DuPont de Nemours (DD) 10-Q 5 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - $ / shares	3 Months Ended
	Mar. 31, 2020	May 01, 2020	Dec. 31, 2019
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Entity Registrant Name	DUPONT DE NEMOURS, INC.
Entity File Number	001-38196
Amendment Flag	false
Document Transition Report	false
City Area Code	302
Local Phone Number	774-3034
Entity Central Index Key	0001666700
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-1224539
Entity Address, Address Line One	974 Centre Road
Entity Address, Address Line Two	Building 730
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19805
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	DD
Security Exchange Name	NYSE
Entity Common Stock, Share Outstanding		733,797,258
Par Value	$ 0.01	$ 0.01	$ 0.01

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2020		Mar. 31, 2019
Net sales	$ 5,221		$ 5,414
Cost of sales	3,318		3,621
Research and development expenses	236		267
Selling, general and administrative expenses	633		726
Amortization of intangibles	533		256
Restructuring and asset related charges - net	404		71
Goodwill impairment charge	533	[1]	0
Integration and separation costs	197		611
Equity in earnings of nonconsolidated affiliates	39		40
Sundry income (expense) - net	211		84
Interest expense	183		151
Loss from continuing operations before income taxes	(566)		(165)
Provision for (benefit from) income taxes on continuing operations	44		(91)
Loss from continuing operations, net of tax	(610)		(74)
Income from discontinued operations, net of tax	0		646
Net (loss) income	(610)		572
Net income attributable to noncontrolling interests	6		51
Net (loss) income available for DuPont common stockholders	$ (616)		$ 521
Per common share data:
Loss per common share from continuing operations - basic	$ (0.83)		$ (0.11)
Earnings per common share from discontinued operations - basic	0		0.80
(Loss) Earnings per common share - basic	(0.83)		0.69
Loss per common share from continuing operations - diluted	(0.83)		(0.11)
Earnings per common share from discontinued operations - diluted	0		0.80
(Loss) Earnings per common share - diluted	$ (0.83)		$ 0.69
Weighted-average common shares outstanding - basic	738.6		750
Weighted-average common shares outstanding - diluted	738.6		750
Total Company [Domain]
Goodwill impairment charge	$ 533		$ 0
[1]	See Note 11 for additional information.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net (loss) income	$ (610)	$ 572
Other comprehensive income (loss), net of tax
Unrealized gains (losses) on investments	0	67
Cumulative translation adjustments	(404)	(97)
Pension and other post employment benefit plans	2	135
Derivative instruments	0	(75)
Total other comprehensive (loss) income	(402)	36
Comprehensive (loss) income	(1,012)	602
Comprehensive (loss) income attributable to noncontrolling interests, net of tax	(2)	57
Comprehensive (loss) income attributable to DuPont	(1,010)	545
Total
Other comprehensive income (loss), net of tax
Total other comprehensive (loss) income	$ (394)	$ 30

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 1,748	$ 1,540
Accounts and notes receivable - net	3,869	3,802
Inventories	4,410	4,319
Other current assets	365	338
Total current assets	10,392	9,999
Investments
Investments in nonconsolidated affiliates	1,227	1,204
Other investments	24	24
Noncurrent receivables	31	32
Total investments	1,282	1,260
Property, plant and equipment - net of accumulated depreciation (March 31, 2020 - $5,189; December 31, 2019 - $4,969)	9,912	10,143
Other Assets
Goodwill	32,317	33,151
Other intangible assets	12,834	13,593
Deferred income tax assets	210	236
Deferred charges and other assets	1,040	1,014
Total other assets	46,401	47,994
Total Assets	67,987	69,396
Current Liabilities
Short-term borrowings and finance lease obligations	3,925	3,830
Accounts payable	2,846	2,934
Income taxes payable	340	240
Accrued and other current liabilities	1,434	1,342
Total current liabilities	8,545	8,346
Long-Term Debt	13,618	13,617
Other Noncurrent Liabilities
Deferred income tax liabilities	3,314	3,514
Pension and other post employment benefits - noncurrent	1,155	1,172
Other noncurrent obligations	1,238	1,191
Total other noncurrent liabilities	5,707	5,877
Total Liabilities	27,870	27,840
Stockholders' Equity
Common stock (authorized 1,666,666,667 shares of $0.01 par value each; issued 2020: 733,793,781 shares; 2019: 738,564,728 shares)	7	7
Additional paid-in capital	50,605	50,796
(Accumulated deficit) Retained earnings	(9,251)	(8,400)
Accumulated other comprehensive loss	(1,810)	(1,416)
Total DuPont stockholders' equity	39,551	40,987
Noncontrolling interests	566	569
Total equity	40,117	41,556
Total Liabilities and Equity	$ 67,987	$ 69,396

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Accumulated depreciation	$ 5,189	$ 4,969
Shares Authorized	1,666,666,667	1,666,666,667
Par Value	$ 0.01	$ 0.01
Shares Issued	733,793,781	738,564,728

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended			10 Months Ended
	Mar. 31, 2020		Mar. 31, 2019	Mar. 31, 2020
Operating Activities
Net (loss) income	$ (610)		$ 572
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	772
Goodwill impairment charge	533	[1]	0
Financing Activities
Purchases of common stock	(232)			$ (982)
Cash, cash equivalents and restricted cash at beginning of period	1,577		14,022
Cash, cash equivalents and restricted cash at end of period	1,782		12,066	1,782
Continuing Operations [Member]
Financing Activities
Cash, cash equivalents and restricted cash at beginning of period	1,577		8,591
Cash, cash equivalents and restricted cash at end of period	1,782		6,862	1,782
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member]
Financing Activities
Cash, cash equivalents and restricted cash at beginning of period	0		5,431
Cash, cash equivalents and restricted cash at end of period	0		5,204	$ 0
Total Company [Domain]
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	772		1,520
Credit for deferred income tax and other tax related items	(164)		(368)
Earnings of nonconsolidated affiliates less than (in excess of) dividends received	(31)		767
Net periodic pension benefit (credit) cost	7		(8)
Pension contributions	(26)		(153)
Net gain on sales of assets, businesses and investments	(197)		(43)
Restructuring and asset related charges - net	404		287
Goodwill impairment charge	533		0
Amortization of merger-related inventory step-up	0		205
Other net loss	49		93
Accounts and notes receivable	(134)		(1,643)
Inventories	(134)		(194)
Accounts payable	236		(732)
Other assets and liabilities, net	13		(277)
Cash provided by operating activities	718		26
Investing Activities
Capital expenditures	(481)		(1,139)
Investment in gas field developments	0		(25)
Proceeds from sales of property and businesses, net of cash divested	427		125
Acquisitions of property and businesses, net of cash acquired	(73)		0
Proceeds from sale of ownership interests in nonconsolidated affiliates	0		21
Purchases of investments	(1)		(189)
Proceeds from sales and maturities of investments	0		212
Other investing activities, net	4		(5)
Cash used for investing activities	(124)		(1,000)
Financing Activities
Changes in short-term notes payable	69		798
Proceeds from issuance of long-term debt	25		1,000
Payments on long-term debt	(1)		(363)
Purchases of common stock	(232)		(1,579)
Proceeds from issuance of Company stock	34		63
Employee taxes paid for share-based payment arrangements	(12)		(76)
Distributions to noncontrolling interests	(6)		(11)
Dividends paid to stockholders	(222)		(851)
Debt extinguishment costs	0		(13)
Other financing activities, net	1		0
Cash used for financing activities	(344)		(1,032)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(45)		50
Increase (Decrease) in cash, cash equivalents and restricted cash	$ 205		$ (1,956)
[1]	See Note 11 for additional information.

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Common Stock	Add'l Paid in Capital	Retained Earnings (Accumulated Deficit)	Accumulated Other Comp Loss	Unearned ESOP	Treasury Stock	Non-controlling Interests
Beginning balance at Dec. 31, 2018	$ 95,900	$ 8	$ 81,976	$ 30,257	$ (12,394)	$ (134)	$ (5,421)	$ 1,608
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adoption of accounting standards	(111)			(111)
Net (loss) income	572			521				51
Other comprehensive income	36				30			6
Dividends	(1,176)			(1,176)
Common stock issued/sold	63		63
Stock-based compensation and allocation of ESOP shares	131		102			29
Distributions to non-controlling interests	(11)							(11)
Purchases of treasury stock	(1,579)						(1,579)
Other	(5)			(5)
Ending balance at Mar. 31, 2019	93,820	8	82,141	29,486	(12,364)	(105)	(7,000)	1,654
Beginning balance at Dec. 31, 2019	41,556	7	50,796	(8,400)	(1,416)	0	0	569
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adoption of accounting standards	(3)			(3)
Net (loss) income	(610)			(616)				6
Other comprehensive income	(402)				(394)			(8)
Dividends	(222)		(222)
Common stock issued/sold	34		34
Stock-based compensation and allocation of ESOP shares	30		30
Distributions to non-controlling interests	(6)							(6)
Purchases of treasury stock	(232)						(232)
Retirement of treasury stock	0			(232)			232
Other	(28)		(33)					5
Ending balance at Mar. 31, 2020	$ 40,117	$ 7	$ 50,605	$ (9,251)	$ (1,810)	$ 0	$ 0	$ 566

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Stockholders' Equity [Abstract]
Common stock dividends (in dollars per share)	$ 0.3	$ 1.56

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Interim Financial Statements The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the interim statements reflect all adjustments (including normal recurring accruals) which are considered necessary for the fair statement of the results for the periods presented. Results from interim periods should not be considered indicative of results for the full year. These interim Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, collectively referred to as the “2019 Annual Report.” The interim Consolidated Financial Statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Impact of the Novel Coronavirus (“COVID-19”) Pandemic The COVID-19 pandemic has resulted in significant economic disruption and continues to adversely impact the broader global economy. The extent of the impact on the Company's operational and financial performance will depend on future developments, including, but not limited to, the duration and spread of the outbreak and its impact on the Company's customers and suppliers. As of the date of issuance of these interim Consolidated Financial Statements, the full extent to which the COVID-19 pandemic may materially impact the Company's financial condition, liquidity, or results of operations is uncertain. Basis of Presentation Effective August 31, 2017, pursuant to the merger of equals transaction contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 ("Merger Agreement"), The Dow Chemical Company ("Historical Dow") and E. I. du Pont de Nemours and Company ("Historical EID") each merged with subsidiaries of DowDuPont Inc. ("DowDuPont") and, as a result, Historical Dow and Historical EID became subsidiaries of DowDuPont (the "Merger"). Prior to the Merger, DowDuPont did not conduct any business activities other than those required for its formation and matters contemplated by the Merger Agreement. Historical Dow was determined to be the accounting acquirer in the Merger. Except as otherwise indicated by the context, the term "Historical Dow" includes Historical Dow and its consolidated subsidiaries, "Historical EID" includes Historical EID and its consolidated subsidiaries, and "Dow Silicones" means Dow Silicones Corporation, a wholly owned subsidiary of Historical Dow. Distributions Effective as of 5:00 p.m. on April 1, 2019, the Company completed the separation of its materials science business into a separate and independent public company by way of a distribution of Dow Inc. (“Dow”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock (the “Dow Common Stock”), to holders of the Company’s common stock (the “DowDuPont common stock”), as of the close of business on March 21, 2019 (the “Dow Distribution”). Effective as of 12:01 a.m. on June 1, 2019, the Company completed the separation of its agriculture business into a separate and independent public company by way of a distribution of Corteva, Inc. (“Corteva”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Corteva’s common stock (the “Corteva Common Stock”), to holders of the Company’s common stock as of the close of business on May 24, 2019 (the “Corteva Distribution” and, together with the Dow Distribution, the “Distributions”). Following the Corteva Distribution, DuPont holds the specialty products business. On June 1, 2019, DowDuPont changed its registered name from "DowDuPont Inc." to "DuPont de Nemours, Inc." doing business as "DuPont." Beginning on June 3, 2019, the Company's common stock is traded on the NYSE under the ticker symbol "DD". The results of operations of DuPont for the three months ended March 31, 2019 present the historical financial results of Dow and Corteva as discontinued operations. The cash flows and comprehensive income related to Dow and Corteva have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for the applicable period. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of Dow or Corteva. On December 15, 2019, the Company entered into definitive agreements to separate and combine the Nutrition & Biosciences business segment (the "N&B Business") with International Flavors & Fragrances Inc. ("IFF") in a tax-efficient Reverse Morris Trust transaction, (the "Proposed N&B Transaction"). The transaction is expected to close by the end of the first quarter of 2021, subject to approval by IFF shareholders and other customary closing conditions, including regulatory approvals and receipt by

RECENT ACCOUNTING GUIDANCE (Not

RECENT ACCOUNTING GUIDANCE (Notes)	3 Months Ended
	Mar. 31, 2020
Recent Accounting Guidance [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	RECENT ACCOUNTING GUIDANCE Recently Adopted Accounting Guidance In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and associated ASUs related to Topic 326. The new guidance introduces the current expected credit loss (“CECL”) model, which requires organizations to record an allowance for credit losses for certain financial instruments and financial assets, including trade receivables, based on expected losses rather than incurred losses. Under this update, on initial recognition and at each reporting period, an entity will be required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. This update became effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the new standard in the first quarter of 2020, which required a modified retrospective transition approach, applying the new standard's cumulative-effect adjustment at the date of initial adoption. This cumulative-effect has been reflected as of January 1, 2020 and prior periods have not been restated. The impact of initial adoption was not material to the Company’s interim Condensed Consolidated Balance Sheet, interim Consolidated Statements of Operations, and interim Consolidated Statement of Cash Flows.

DIVESTITURES (Notes)

DIVESTITURES (Notes)	3 Months Ended
	Mar. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	DIVESTITURES Separation Agreements In connection with the Dow Distribution and the Corteva Distribution, the Company entered into certain agreements that, among other things, effected the separations, provides for the allocation of assets, employees, liabilities and obligations (including its investments, property and employee benefits and tax-related assets and liabilities) among DuPont, Dow, and Corteva (together, the “Parties” and each a “Party”), and provides a framework for DuPont’s relationship with Dow and Corteva following the Distributions. Effective April 1, 2019, the Parties entered into the following agreements: the Separation and Distribution Agreement; the Tax Matters Agreement; the Employee Matters Agreement; and the Intellectual Property Cross-License Agreement (the “DuPont-Dow IP Cross-License Agreement”). In addition to the agreements above, DuPont has entered into certain various supply agreements with Dow. These agreements provide for different pricing than the historical intercompany and intracompany practices prior to the Distributions. Effective June 1, 2019, in connection with the Corteva Distribution, DuPont and Corteva entered into the following agreements: the Intellectual Property Cross-License Agreement (the “DuPont-Corteva IP Cross-License Agreement”); the Letter Agreement; and the Amended and Restated Tax Matters Agreement. Materials Science Division On April 1, 2019, DowDuPont completed the separation of its Materials Science businesses, including the businesses and operations that comprised the Company's former Performance Materials & Coating, Industrial Intermediates & Infrastructure and the Packaging & Specialty Plastics segments, (the "Materials Science Division") through the consummation of the Dow Distribution. On April 1, 2019, prior to the Dow Distribution, the Company contributed $2,024 million in cash to Dow. The results of operations of the Materials Science Division are presented as discontinued operations as summarized below: Three Months Ended In millions Net sales $ 10,867 Cost of sales 8,917 Research and development expenses 163 Selling, general and administrative expenses 329 Amortization of intangibles 116 Restructuring and asset related charges - net 157 Integration and separation costs 44 Equity in earnings of nonconsolidated affiliates (13 ) Sundry income (expense) - net 99 Interest expense 240 Income from discontinued operations before income taxes 987 Provision for income taxes on discontinued operations 261 Income from discontinued operations, net of tax 726 Income from discontinued operations attributable to noncontrolling interests, net of tax 37 Income from discontinued operations attributable to DuPont stockholders, net of tax $ 689 The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the Materials Science Division: Three Months Ended In millions Depreciation and amortization $ 744 Capital expenditures $ 597 Agriculture Division On June 1, 2019, the Company completed the separation of its Agriculture business, including the businesses and operations that comprised the Company's former Agriculture segment (the "Agriculture Division"), through the consummation of the Corteva Distribution. In 2019, prior to the distribution of Corteva, the Company contributed $7,139 million in cash to Corteva, a portion of which was used to retire indebtedness of Historical EID. The results of operations of the Agriculture Division are presented as discontinued operations as summarized below: Three Months Ended In millions Net sales $ 3,368 Cost of sales 2,192 Research and development expenses 287 Selling, general and administrative expenses 617 Amortization of intangibles 102 Restructuring and asset related charges - net 59 Integration and separation costs 158 Equity in earnings of nonconsolidated affiliates (1 ) Sundry income (expense) - net 65 Interest expense 63 Income from discontinued operations before income taxes (46 ) Provision for income taxes on discontinued operations 34 Income from discontinued operations, net of tax (80 ) Income from discontinued operations attributable to noncontrolling interests, net of tax 10 Income from discontinued operations attributable to DuPont stockholders, net of tax $ (90 ) The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the Agriculture Division: Three Months Ended In millions Depreciation and amortization $ 249 Capital expenditures $ 222 Indemnifications In connection with the Distributions, Dow and Corteva indemnify the Company against, and DuPont indemnifies Dow and Corteva against certain litigation, environmental, income taxes, workers' compensation and other liabilities that arose prior to the Distributions, as applicable. The term of this indemnification is indefinite and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. At March 31, 2020 , the indemnified assets were $134 million within "Accounts and notes receivable, net" and $141 million within "Deferred charges and other assets" and indemnified liabilities were $80 million within "Accrued and other current liabilities" and $95 million within "Other noncurrent obligations." Refer to Note 13 for additional information regarding treatment of litigation and environmental related matters under the Separation and Distribution Agreement and the Letter Agreement. Sale of Compound Semiconductor Solutions In the first quarter of 2020, the Company completed the sale of its Compound Semiconductor Solutions business unit, a part of the Electronics & Imaging segment, to SK Siltron. The proceeds received in the first quarter of 2020 related to the sale of the business were approximately $420 million . The sale resulted in a pre-tax gain of $197 million ( $102 million net of tax) recorded in "Sundry income (expense) - net" in the Company's interim Consolidated Statements of Operations for the three months ended March 31, 2020. Integration and Separation Costs Integration and separation costs for continuing operations to date primarily have consisted of financial advisory, information technology, legal, accounting, consulting, and other professional advisory fees associated with the preparation and execution of activities related to the Merger, post-Merger integration, the Distributions, and beginning in the fourth quarter of 2019, the intended separation of the Nutrition & Biosciences business. These costs are recorded within "Integration and separation costs" within the interim Consolidated Statements of Operations. Three Months Ended March 31, In millions 2020 2019 Integration and separation costs $ 197 $ 611

REVENUE

REVENUE	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	REVENUE Revenue Recognition Products Substantially all of DuPont's revenue is derived from product sales. Product sales consist of sales of DuPont's products to supply manufacturers and distributors. DuPont considers purchase orders, which in some cases are governed by master supply agreements, to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year. Disaggregation of Revenue The Company disaggregates its revenue from contracts with customers by segment and business or major product line and geographic region, as the Company believes it best depicts the nature, amount, timing and uncertainty of its revenue and cash flows. Net Trade Revenue by Segment and Business or Major Product Line Three Months Ended March 31, In millions 2020 2019 Image Solutions $ 148 $ 154 Interconnect Solutions 266 238 Semiconductor Technologies 470 433 Electronics & Imaging $ 884 $ 825 Food & Beverage $ 738 $ 755 Health & Biosciences 605 570 Pharma Solutions 208 210 Nutrition & Biosciences $ 1,551 $ 1,535 Healthcare & Specialty $ 359 $ 384 Industrial & Consumer 266 308 Mobility Solutions 519 625 Transportation & Industrial $ 1,144 $ 1,317 Safety Solutions $ 631 $ 665 Shelter Solutions 348 357 Water Solutions 297 261 Safety & Construction $ 1,276 $ 1,283 Biomaterials $ 34 $ 59 Clean Technologies 60 65 DuPont Teijin Films 43 37 Photovoltaic & Advanced Materials 229 254 Sustainable Solutions 1 — 39 Non-Core $ 366 $ 454 Total $ 5,221 $ 5,414 1. The Sustainable Solutions business was divested in the third quarter of 2019. Net Trade Revenue by Geographic Region Three Months Ended March 31, In millions 2020 2019 U.S. & Canada $ 1,742 $ 1,776 EMEA 1 1,271 1,380 Asia Pacific 1,913 1,945 Latin America 295 313 Total $ 5,221 $ 5,414 1. Europe, Middle East and Africa. Contract Balances From time to time, the Company enters into arrangements in which it receives payments from customers based upon contractual billing schedules. The Company records accounts receivables when the right to consideration becomes unconditional. Contract assets include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Contract liabilities primarily reflect deferred revenue from advance payment for product that the Company has received from customers. The Company classifies deferred revenue as current or noncurrent based on the timing of when the Company expects to recognize revenue. Revenue recognized in the first three months of 2020 from amounts included in contract liabilities at the beginning of the period was approximately $14 million (approximately $10 million in the first three months of 2019 ). The amount of contract assets reclassified to receivables as a result of the right to the transaction consideration becoming unconditional was insignificant. The Company did not recognize any asset impairment charges related to contract assets during the period. Contract Balances March 31, 2020 December 31, 2019 In millions Accounts and notes receivable - trade 1 $ 3,156 $ 3,007 Contract assets - current 2 $ 32 $ 35 Deferred revenue - current 3 $ 69 $ 43 Deferred revenue - noncurrent 4 $ 29 $ 34 1. Included in "Accounts and notes receivable - net" in the interim Condensed Consolidated Balance Sheets. 2. Included in "Other current assets" in the interim Condensed Consolidated Balance Sheets. 3. Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets. 4.

RESTRUCTURING AND ASSET RELATED

RESTRUCTURING AND ASSET RELATED CHARGES - NET (Notes)	3 Months Ended
	Mar. 31, 2020
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	RESTRUCTURING AND ASSET RELATED CHARGES - NET Charges for restructuring programs and asset related charges, which includes other asset impairments, were $404 million for the three months ended March 31, 2020 ( $71 million for the three ended March 31, 2019 ). These charges were recorded in "Restructuring and asset related charges - net" in the interim Consolidated Statements of Operations. The total liability related to restructuring programs was $230 million at March 31, 2020 ( $162 million at December 31, 2019). Restructuring activity consists of the following: 2020 Restructuring Program In the first quarter of 2020, the Company approved restructuring actions designed to capture near-term cost reductions and to further simplify certain organizational structures in anticipation of the expected closure of the Proposed N&B Transaction (the "2020 Restructuring Program"). As a result of these actions, the Company expects to record total pre-tax restructuring charges up to $180 million , comprised of $125 million of severance and related benefit costs, $50 million of asset related charges, and $5 million of costs related to contract terminations. For the three months ended March 31, 2020, DuPont recorded a pre-tax charge related to the 2020 Restructuring Program in the amount of $111 million , recognized in "Restructuring and asset related charges - net" in the Company's interim Consolidated Statement of Operations, comprised of $96 million of severance and related benefit costs and $15 million of asset related charges. At March 31, 2020, total liabilities related to the 2020 Restructuring Program were $96 million for severance and related benefit costs, recognized in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets. The following table summarizes the charges incurred by segment related to the 2020 Restructuring Program: 2020 Restructuring Program Charges by Segment Three Months Ended March 31, 2020 In millions Electronics & Imaging $ 4 Nutrition & Biosciences 6 Transportation & Industrial 24 Safety & Construction 20 Non-Core — Corporate 57 Total $ 111 The Company expects actions related to this program to be substantially complete by the end of 2020. 2019 Restructuring Program During the second quarter 2019 and in connection with the ongoing integration activities, DuPont approved restructuring actions to simplify and optimize certain organizational structures following the completion of the Distributions (the "2019 Restructuring Program"). The Company has recorded pre-tax restructuring charges of $156 million inception-to-date, consisting of severance and related benefit costs of $122 million and asset related charges of $34 million . The Company incurred charges for severance and related benefit costs of $18 million related to the 2019 Restructuring Program during the three months ended March 31, 2020 . These charges consisted of $1 million related to the Transportation & Industrial segment and $17 million related to Corporate. The following table summarizes the activities related to the 2019 Restructuring Program: 2019 Restructuring Program Severance and Related Benefit Costs In millions Reserve balance at December 31, 2019 $ 86 Current quarter restructuring charges 18 Non-cash compensation (6 ) Cash payments (23 ) Reserve balance at March 31, 2020 $ 75 At March 31, 2020 , the $75 million for severance and related benefit costs was included in "Accrued and other current liabilities" ( $86 million at December 31, 2019) in the interim Condensed Consolidated Balance Sheets. The Company expects actions related to this program to be substantially complete in the second quarter of 2020. DowDuPont Cost Synergy Program In September and November 2017, the Company approved post-merger restructuring actions under the DowDuPont Cost Synergy Program, which was designed to integrate and optimize the organization following the Merger and in preparation for the Distributions of Dow and Corteva. The portions of the charges, costs and expenses attributable to integration and optimization within the Agriculture and Materials Science Divisions are reflected in discontinued operations. The Company has recorded pre-tax restructuring charges attributable to the continuing operations of DuPont of $490 million inception-to-date, consisting of severance and related benefit costs of $215 million , asset related charges of $209 million and contract termination charges of $66 million related to charges. The following tables summarize the charges incurred related to the DowDuPont Cost Synergy Program: Three Months Ended March 31, In millions 2020 2019 Severance and related benefit costs $ — $ 43 Contract termination charges 5 16 Asset related charges — 13 Total restructuring and asset related charges - net 1,2 $ 5 $ 72 1. The charges for the three months ended March 31, 2020 include $5 million related to Safety and Construction. 2. The charges for the three months ended March 31, 2019 include $27 million related to Nutrition & Biosciences, $2 million related to Safety and Construction, $44 million related to Corporate, and a benefit of $1 million related to Non Core. Charges for the three months ended March 31, 2020 and 2019 include $5 million and $71 million , respectively, recognized in "Restructuring and asset related charges - net." The charge for the three months ended March 31, 2019 also includes $1 million recognized in "Equity in earnings of nonconsolidated affiliates" in the interim Consolidated Statements of Operations. The following table summarizes the activities related to the DowDuPont Cost Synergy Program: DowDuPont Cost Synergy Program Severance and Related Benefit Costs Contract Termination Charges Total In millions Reserve balance at December 31, 2019 $ 74 $ 2 $ 76 Current quarter restructuring charges — 5 5 Cash payments (22 ) — (22 ) Reserve balance at March 31, 2020 $ 52 $ 7 $ 59 At March 31, 2020 , the $59 million was included in "Accrued and other current liabilities" ( $76 million at December 31, 2019) in the interim Condensed Consolidated Balance Sheets. The DowDuPont Cost Synergy Program is considered substantially complete at March 31, 2020. Asset Impairments The Company reviews and evaluates its long-lived assets for impairment when events and changes in circumstances indicate that the related carrying amount of such assets may not be recoverable and may exceed their fair value. For purposes of determining impairment, assets are grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. In the first quarter of 2020, expectations of proceeds related to certain potential divestitures within the Non-Core segment gave rise to fair value indicators and, thus, triggering events requiring the Company to perform a recoverability assessment related to its biomaterials business unit. The Company performed a long-lived asset impairment test and determined that, based on undiscounted cash flows, the carrying amount of certain long-lived assets was not recoverable. Accordingly, the Company estimated the fair value of these assets using a market approach utilizing Level 3 unobservable inputs. As a result, the Company recognized a $270 million pre-tax impairment charge recorded within “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operation for the three months ended March 31, 2020 with the charge impacting definite-lived intangible assets and property, plant, and equipment.

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUPPLEMENTARY INFORMATION	SUPPLEMENTARY INFORMATION Sundry Income (Expense) - Net Three Months Ended March 31, In millions 2020 2019 Non-operating pension and other post employment benefit (OPEB) credits $ 11 $ 21 Interest income 2 40 Net gain on divestiture and sales of other assets and investments 1,2 197 53 Foreign exchange (losses) gains, net (8 ) (61 ) Miscellaneous income (expenses) - net 3 9 31 Sundry income (expense) - net $ 211 $ 84 1. The three months ended March 31, 2020 reflects income of $197 million related to the gain on sale of the Compound Semiconductor Solutions business unit within the Electronics & Imaging segment. 2. The three months ended March 31, 2019 includes income of $51 million related to a sale of assets within the Electronics & Imaging segment. 3. Miscellaneous income (expenses) - net for the three months ended March 31, 2019 includes $26 million related to licensing income within the Safety & Construction segment. Cash, Cash Equivalents and Restricted Cash From time to time, the Company is required to set aside funds for various activities that arise in the normal course of business. These funds typically have legal restrictions associated with them and are deposited in an escrow account or held in a separately identifiable account by the Company. Historical EID entered into a trust agreement in 2013 (as amended and restated in 2017), establishing and requiring Historical EID to fund a trust (the "Trust") for cash obligations under certain non-qualified benefit and deferred compensation plans upon a change in control event as defined in the Trust agreement. Under the Trust agreement, the consummation of the Merger was a change in control event. After the distribution of Corteva, the Trust assets related to Corteva employees were transferred to a new trust for Corteva (the "Corteva Trust"). As a result, the Trust currently held by DuPont relates to funding obligations to DuPont employees. At March 31, 2020 , the Company had restricted cash of $34 million ( $37 million at December 31, 2019 ) included in "Other current assets" in the interim Condensed Consolidated Balance Sheets which was completely attributed to the Trust. Accrued and Other Current Liabilities "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets were $1,434 million at March 31, 2020 and $1,342 million at December 31, 2019 . No component of "Accrued and other current liabilities" was more than 5 percent of total current liabilities at March 31, 2020 . Accrued payroll, which is a component of "Accrued and other current liabilities," was $479 million at December 31, 2019 . No other component of "Accrued and other current liabilities" was more than 5 percent of total current liabilities at December 31, 2019

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES For periods between the Merger and the Distributions, DuPont's consolidated federal income tax group and consolidated tax return included the Dow and Corteva entities. Generally, the consolidated tax liability of the DuPont U.S. tax group for each year was apportioned among the members of the consolidated group in accordance with the terms of the Amended and Restated Tax Matters Agreement. DuPont, Corteva and Dow intend that to the extent Federal and/or State corporate income tax liabilities are reduced through the utilization of tax attributes of the other, settlement of any receivable and payable generated from the use of the other party’s sub-group attributes will be in accordance with the Amended and Restated Tax Matters Agreement. The Company's effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attributes. The effective tax rate on continuing operations for the first quarter of 2020 was (7.8) percent , compared with an effective tax rate of 55.2 percent for the first quarter of 2019 . The effective tax rate for the first quarter of 2020 was principally the result of the non-tax-deductible goodwill impairment charge impacting the Non-core segment. See Note 11 for more information regarding the goodwill impairment charge. Each year the Company files hundreds of tax returns in the various national, state and local income taxing jurisdictions in which it operates. These tax returns are subject to examination and possible challenge by the tax authorities. Positions challenged by the tax authorities may be settled or appealed by the Company. As a result, there is an uncertainty in income taxes recognized in the Company’s financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes. The ultimate resolution of such uncertainties is not expected to have a material impact on the Company's results of operations.

EARNINGS PER SHARE CALCULATIONS

EARNINGS PER SHARE CALCULATIONS	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
EARNINGS PER SHARE CALCULATIONS	EARNINGS PER SHARE CALCULATIONS The following tables provide earnings per share calculations for the three months ended March 31, 2020 and 2019 : Net Income for Earnings Per Share Calculations - Basic & Diluted Three Months Ended March 31, In millions 2020 2019 Loss from continuing operations, net of tax $ (610 ) $ (74 ) Net income from continuing operations attributable to noncontrolling interests 6 4 Net income from continuing operations attributable to participating securities 1 — 1 Loss from continuing operations attributable to common stockholders $ (616 ) $ (79 ) Income from discontinued operations, net of tax — 646 Net income from discontinued operations attributable to noncontrolling interests — 47 Income from discontinued operations attributable to common stockholders — 599 Net (loss) income attributable to common stockholders $ (616 ) $ 520 Earnings Per Share Calculations - Basic Three Months Ended March 31, Dollars per share 2020 2019 Loss from continuing operations attributable to common stockholders $ (0.83 ) $ (0.11 ) Income from discontinued operations, net of tax — 0.80 Net (loss) income attributable to common stockholders $ (0.83 ) $ 0.69 Earnings Per Share Calculations - Diluted Three Months Ended March 31, Dollars per share 2020 2019 Loss from continuing operations attributable to common stockholders $ (0.83 ) $ (0.11 ) Income from discontinued operations, net of tax — 0.80 Net (loss) income attributable to common stockholders $ (0.83 ) $ 0.69 Share Count Information Three Months Ended March 31, Shares in millions 2020 2019 Weighted-average common shares - basic 738.6 750.0 Plus dilutive effect of equity compensation plans — — Weighted-average common shares - diluted 738.6 750.0 Stock options and restricted stock units excluded from EPS calculations 2 6.4 6.4 1. Historical Dow restricted stock units are considered participating securities due to Historical Dow's practice of paying dividend equivalents on unvested shares. 2. These outstanding options to purchase shares of common stock and restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive.

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	INVENTORIES Inventories March 31, 2020 December 31, 2019 In millions Finished goods $ 2,731 $ 2,621 Work in process 858 855 Raw materials 589 599 Supplies 232 244 Total inventories $ 4,410 $ 4,319

NONCONSOLIDATED AFFILIATES (Not

NONCONSOLIDATED AFFILIATES (Notes)	3 Months Ended
	Mar. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NONCONSOLIDATED AFFILIATES The Company's investments in companies accounted for using the equity method ("nonconsolidated affiliates"), by classification in the interim Condensed Consolidated Balance Sheets, are shown in the following table: Investments in Nonconsolidated Affiliates Mar 31, 2020 Dec 31, 2019 In millions Investments in nonconsolidated affiliates $ 1,227 $ 1,204 Accrued and other current liabilities (84 ) (85 ) Other noncurrent obligations (351 ) (358 ) Net investment in nonconsolidated affiliates $ 792 $ 761 The Company maintained an ownership interest in 21 nonconsolidated affiliates at March 31, 2020 . The following table reflects the Company's principal nonconsolidated affiliates and its ownership interest (direct and indirect) for each at March 31, 2020 : Country Ownership Interest March 31, 2020 The HSC Group: DC HSC Holdings LLC 1 United States 50.0 % Hemlock Semiconductor L.L.C. United States 50.1 % 1. DC HSC Holdings LLC holds an 80.5 percent indirect ownership interest in Hemlock Semiconductor Operations LLC. Sales to nonconsolidated affiliates represented less than 3 percent of total net sales for the three months ended March 31, 2020 and 2019. Sales to nonconsolidated affiliates are primarily related to the sale of trichlorosilane, a raw material used in the production of polycrystalline silicon, to the HSC Group. Sales of this raw material to the HSC Group are reflected in Non-Core. Purchases from nonconsolidated affiliates represented approximately 2 percent of “Cost of sales” for the three months ended March 31, 2020 and 2019. HSC Group The following table reflects the carrying value of the HSC Group investments at March 31, 2020 and December 31, 2019 : Investment in the HSC Group Investment In millions Balance Sheet Classification Mar 31, 2020 Dec 31, 2019 Hemlock Semiconductor L.L.C. Other noncurrent obligations $ (351 ) $ (358 ) DC HSC Holdings LLC Investments in nonconsolidated affiliates $ 97 $ 87 The following is summarized financial information for the Company's principal nonconsolidated equity method investments. The amounts shown below represent 100 percent of these equity method investments' results of operations: Results of Operations Three Months Ended March 31, In millions 2020 2019 Revenues 1 $ 185 $ 185 Cost of sales 1 $ 127 $ 107 Income from continuing operations $ 40 $ 63 Net income attributed to entities $ 35 $ 52 1. Includes sales and cost of sales of $22 million and $21 million for the three months ended March 31, 2020 and 2019, respectively, that have not been eliminated between Hemlock Semiconductor L.L.C and DC HSC Holdings in the presentation of the summarized income statement information above.

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS The changes in the carrying amounts of goodwill during the three months ended March 31, 2020 were as follows: Elect. & Imaging Nutrition & Biosciences Transp. & Industrial Safety & Const. Non-Core Total In millions Balance at December 31, 2019 $ 7,092 $ 11,012 $ 6,931 $ 6,711 $ 1,405 $ 33,151 Acquisitions — — — 53 — 53 Divestitures (199 ) — — — — (199 ) Impairments — — — — (533 ) (533 ) Currency Translation Adjustment (11 ) (111 ) (25 ) (26 ) — (173 ) Measurement Period Adjustments — — — 18 — 18 Balance at March 31, 2020 $ 6,882 $ 10,901 $ 6,906 $ 6,756 $ 872 $ 32,317 The Company tests goodwill for impairment annually during the fourth quarter as of October 1, or more frequently when events or changes in circumstances indicate that fair value is below carrying value. As a result of the related acquisition method of accounting in connection with the Merger, Historical EID’s assets and liabilities were measured at fair value resulting in increases to the Company’s goodwill and other intangible assets. The fair value valuation increased the risk that declines in financial projections, including changes to key assumptions, could have a material, negative impact on the fair value of the Company’s reporting units and assets, and therefore could result in an impairment. Expectations of proceeds related to certain potential divestitures within the Non-Core segment gave rise to fair value indicators and, thus, served as triggering events requiring the Company to perform impairment analyses related to goodwill. As part of the analysis, the Company determined that the fair value of its Photovoltaic and Advanced Materials (“PVAM”) reporting unit was below its carry value resulting in an impairment charge to goodwill. Valuations of the PVAM reporting unit under a combination of the market approach and income approach reflect softening conditions in photovoltaics markets as compared to prior estimates. In connection with this analysis, the Company recorded a pre-tax, non-cash impairment charge of $533 million for the three months ended March 31, 2020 impacting the Non-Core segment. The Company's analysis uses the discounted cash flow model (a form of the income approach) utilizing Level 3 unobservable inputs. The Company’s significant assumptions in this analysis include, but are not limited to, future cash flow projections, the weighted average cost of capital, the terminal growth rate, and the tax rate. The Company’s estimates of future cash flows are based on current regulatory and economic climates, recent operating results, and planned business strategies. These estimates could be negatively affected by changes in federal, state, or local regulations or economic downturns. Future cash flow estimates are, by their nature, subjective and actual results may differ materially from the Company’s estimates. If the Company’s ongoing estimates of future cash flows are not met, the Company may have to record additional impairment charges in future periods. As referenced, the Company also uses a form of the market approach. As such, the Company believes the current assumptions and estimates utilized are both reasonable and appropriate. COVID-19 continues to adversely impact the broader global economy and has caused significant volatility in financial markets. If there is a of lack of recovery or further global softening in certain markets, mainly in which the Transportation & Industrial segment operates in such as automotive, oil & gas and select industrial end-markets, or a sustained decline in the value of the Company's common stock, the Company may be required to perform additional impairment assessments for its goodwill, other intangibles, and long-lived assets, the results of which could result in material impairment charges. Other Intangible Assets The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows: March 31, 2020 December 31, 2019 In millions Gross Carrying Amount Accum Amort Net Gross Carrying Amount Accum Amort Net Intangible assets with finite lives: Developed technology $ 4,356 $ (1,523 ) $ 2,833 $ 4,343 $ (1,361 ) $ 2,982 Trademarks/tradenames 2,416 (755 ) 1,661 2,433 (455 ) 1,978 Customer-related 8,920 (2,339 ) 6,581 8,986 (2,229 ) 6,757 Other 300 (214 ) 86 303 (98 ) 205 Total other intangible assets with finite lives $ 15,992 $ (4,831 ) $ 11,161 $ 16,065 $ (4,143 ) $ 11,922 Intangible assets with indefinite lives: Trademarks/tradenames 1,673 — 1,673 1,671 — 1,671 Total other intangible assets 1,673 — 1,673 1,671 — 1,671 Total $ 17,665 $ (4,831 ) $ 12,834 $ 17,736 $ (4,143 ) $ 13,593 During the first quarter of 2020, the Company recorded non-cash impairment charges related to definite-lived intangible assets impacting the Non-Core segment. See Note 5 for further discussion. The following table provides the net carrying value of other intangible assets by segment: Net Intangibles by Segment Mar 31, 2020 Dec 31, 2019 In millions Electronics & Imaging $ 1,764 $ 1,833 Nutrition & Biosciences 3,989 4,377 Transportation & Industrial 3,524 3,590 Safety & Construction 3,048 3,082 Non-Core 509 711 Total $ 12,834 $ 13,593 The following table provides information regarding amortization expense related to other intangible assets: Amortization Expense Three Months Ended March 31, In millions 2020 2019 Other intangible assets $ 533 $ 256 Total estimated amortization expense for the remainder of 2020 and the five succeeding fiscal years is as follows: Estimated Amortization Expense In millions 2020 $ 1,595 2021 $ 1,008 2022 $ 968 2023 $ 925 2024 $ 826 2025 $ 789

SHORT TERM BORROWINGS, LONG-TER

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES	SHORT-TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES Debt Offering On May 1, 2020, the Company completed an underwritten public offering of senior unsecured notes (the “Notes”) in the aggregate principal amount of $2 billion of 2.169 percent fixed rate Notes due May 1, 2023 (the “May Debt Offering”). The proceeds from the May Debt Offering are expected to be used by the Company to repay or redeem the Company’s $0.5 billion in floating rate notes due November 2020 and $1.5 billion of 3.77 percent fixed-rate notes due November 2020 (collectively, the “2020 Notes”). Upon consummation of the Proposed N&B Transaction, the Company will be required to mail a notice of redemption to holders of the Notes, with a copy to the Trustee, setting forth the date of redemption of all of the Notes on the date (“Special Mandatory Redemption Date”) that is the later of (i) three (3) Business Days after the consummation of the Proposed N&B Transaction and (ii) May 1, 2021. On the Special Mandatory Redemption Date, the Company will be required to redeem all of the Notes at a redemption price equal to 100% of the aggregate principal amount of the Notes plus accrued and unpaid interest, if any, up to but excluding the Special Mandatory Redemption Date. The Indenture also contains certain limitations on the Company’s ability to incur liens and enter into sale lease-back transactions, as well as customary events of default. Revolving Credit Facility In June 2019, the Company entered into a $750 million , 364-day revolving credit facility (the "Old 364-Day Revolving Credit Facility"). In March 2020, the Company drew down on the Old 364-Day Revolving Credit Facility in the aggregate principal amount of $250 million . In April 2020, the Company repaid the $250 million draw on the Old 364-Day Revolving Credit Facility with interest. On and effective as of April 16, 2020, the Company entered into a new $1.0 billion 364-day revolving credit facility (the “$1B Revolving Credit Facility"). As of the effectiveness of the $1B Revolving Credit Facility, the Old 364-Day Revolving Credit Facility was terminated. Nutrition & Biosciences Financing In connection with the Proposed N&B Transaction, DuPont and Nutrition & Biosciences, Inc. (presently a wholly owned subsidiary of DuPont) (“N&B Inc.”) entered into a Bridge Commitment Letter (the “Bridge Letter”) in an aggregate principal amount of $7.5 billion (the “Bridge Loans”) to secure committed financing for a one-time $7.3 billion cash payment, subject to adjustment, to DuPont ( the "Special Cash Payment") and related financing fees. The aggregate commitment under the Bridge Letter is reduced by, among other things, (1) the amount of net cash proceeds received by N&B Inc. from any issuance of senior unsecured notes pursuant to a Rule 144A offering or other private placement (the "N&B Notes Offering") and (2) certain qualifying term loan commitments under senior unsecured term loan facilities. In January 2020, N&B Inc. entered into a senior unsecured term loan agreement in the amount of $1.25 billion split evenly between three- and five-year facilities. As a result of entry into the term loan agreement, the commitments under the Bridge Commitment Letter were reduced to $6.25 billion

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	COMMITMENTS AND CONTINGENT LIABILITIES Litigation and Environmental Matters As of March 31, 2020, the Company had recorded liabilities of $24 million associated with litigation matters and $77 million associated with environmental matters. These recorded liabilities include the Company’s indemnification obligations to each of Dow and Corteva. Under the Separation and Distribution Agreement, liabilities, including cost and expenses, associated with litigation and environmental matters that primarily related to the materials science business, the agriculture business or the specialty products business were generally allocated to or retained by Dow, Corteva or the Company, respectively, through retention, assumption or indemnification. Related to the foregoing, at March 31, 2020, DuPont has recorded (i) a liability of $35 million (although it is reasonably possible that the ultimate cost could range up to $108 million above the amount accrued) for retained or assumed environmental liabilities, (ii) a liability of $3 million for retained or assumed litigation liabilities, and (iii) an indemnification liability related to legal and environmental matters of $58 million . Liabilities associated with discontinued and/or divested operations and businesses of Historical Dow generally were allocated to or retained by Dow. The allocation of liabilities associated with the discontinued and/or divested operations and businesses of Historical EID is discussed below. Discontinued and/or Divested Operations and Businesses ("DDOB") Liabilities of Historical EID Under the Separation and Distribution Agreement and the Letter Agreement between Corteva and DuPont, DDOB liabilities of Historical EID primarily related to Historical EID’s agriculture business were allocated to or retained by Corteva and those primarily related to Historical EID’s specialty products business were allocated to or retained by the Company. Historical EID DDOB liabilities not primarily related to Historical EID’s agriculture business or specialty products business (“Stray Liabilities”), are allocated as follows: • Generally, indemnifiable losses as defined in the Separation and Distribution Agreement, (“Indemnifiable Losses”) for Stray Liabilities, to the extent they do not arise out of actions related to or resulting from the development, testing, manufacture or sale of PFAS, defined below, (“Non-PFAS Stray Liabilities”) that are known as of April 1, 2019 are borne by Corteva up to a specified amount set forth in the schedules to the Separation and Distribution Agreement and/or Letter Agreement. Non-PFAS Stray Liabilities in excess of such specified amounts and any Non-PFAS Stray Liabilities not listed in the schedules to the Separation and Distribution Agreement or Letter Agreement are borne by Corteva and/or DuPont up to separate, aggregate thresholds of $200 million each to the extent Corteva or DuPont, as applicable, incurs an Indemnifiable Loss. Once Corteva’s or DuPont’s $200 million threshold is met, the other would generally bear all Non-PFAS Stray Liabilities until meeting its $200 million threshold. After the respective $200 million thresholds are met, DuPont will bear 71 percent of such losses and Corteva will bear 29 percent of such losses. • Generally, Corteva and the Company will each bear 50 percent of the first $300 million (up to $150 million each) for Indemnifiable Losses arising out of actions to the extent related to or resulting from the development, testing, manufacture or sale of per- or polyfluoroalkyl substances, which include collectively perfluorooctanoic acids and its salts (“PFOA”), perfluorooctanesulfonic acid (“PFOS”) and perfluorinated chemicals and compounds (“PFCs”) (all such substances, “PFAS” and such Stray Liabilities referred to as “PFAS Stray Liabilities”). Indemnifiable Losses to the extent related to PFAS Stray Liabilities in excess of $300 million generally will be borne 71 percent by the Company and 29 percent by Corteva, unless either Corteva or DuPont has met its $200 million threshold. In that event, the other company would bear all PFAS Stray Liabilities until that company meets its $200 million threshold, at which point DuPont will bear 71 percent of such losses and Corteva will bear 29 percent of such losses. • Indemnifiable Losses incurred by the companies in relation to PFAS Stray Liabilities up to $300 million (e.g., up to $150 million each) will be applied to each company’s respective $200 million threshold. Non-PFAS Stray Liabilities While DuPont believes it is probable that it will incur a liability related to Non-PFAS Stray Liabilities, such liability is not reasonably estimable at March 31, 2020. Therefore, at March 31, 2020, DuPont has not recorded an accrual related to Non-PFAS Liabilities. PFAS Stray Liabilities DuPont expects to continue to incur costs and expenses such as attorneys’ fees and expenses and court costs in connection with the matters described below, which the Company will expense as incurred in accordance with its accounting policy for litigation matters. Chemours Suit On July 1, 2015, Historical EID completed the separation of Historical EID’s Performance Chemicals segment through the spinoff of all the issued and outstanding stock of The Chemours Company (“Chemours”) to holders of Historical EID common stock. In connection with the spin, Historical EID and Chemours entered into a Separation Agreement (as amended, the "Chemours Separation Agreement"). Pursuant to the Chemours Separation Agreement, Chemours is obligated to indemnify Historical EID, including its current or former affiliates, against certain litigation, environmental and other liabilities that arose prior to the Chemours Separation. The term of this indemnification is generally indefinite and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. In 2017, Historical EID and Chemours amended the Chemours Separation Agreement to provide for a limited sharing of potential future PFOA liabilities for a five-year period that began on July 6, 2017. The amended agreement provides that during that five-year period, Chemours will annually pay the first $25 million of future PFOA liabilities and, if that amount is exceeded, Historical EID will pay any excess amount up to the next $25 million , with Chemours annually bearing any excess liabilities above that amount. If Historical EID were required to pay PFOA liabilities pursuant to the amended agreement, fifty percent of such obligation would be borne by the Company in accordance with the Letter Agreement. In connection with the foregoing, the Company has not recorded or paid a PFOA liability. At the end of the five-year period, this limited sharing agreement will expire, and Chemours’ indemnification obligations under the Chemours Separation Agreement will continue unchanged. On May 13, 2019, Chemours filed suit in the Delaware Court of Chancery against Historical EID, Corteva and the Company in an attempt to limit its responsibility for the litigation and environmental liabilities allocated to and assumed by Chemours under the Chemours Separation Agreement. Chemours is asking the court to rewrite the Chemours Separation Agreement by either limiting Chemours’ liabilities or, alternatively, ordering the return to Chemours of all or a portion of a $3.91 billion dividend that Chemours paid to Historical EID, Chemours’ then-sole-shareholder, just prior to the spin of Chemours. DuPont and Corteva, acting jointly, filed a motion to dismiss the lawsuit for lack of subject matter jurisdiction and initiated an arbitration of the dispute as required under the Chemours Separation Agreement. In December 2019, following argument, the Delaware Court of Chancery stayed arbitration pending resolution of the motion to dismiss. On March 30, 2020, the Court of Chancery granted the motion to dismiss and rejected Chemours’ arguments in their entirety. Chemours filed a notice of appeal on April 17, 2020 and may file a motion to stay the arbitration process pending consideration of such an appeal by the Delaware Supreme Court. In the interim, the confidential arbitration process will proceed. Indemnifiable Losses related to the Chemours suit are PFAS Stray Liabilities subject to the sharing arrangement between DuPont and Corteva, described above. The Company believes the probability of a final unappealable judgment of liability with respect to the Chemours suit to be remote; the defendants continue to vigorously defend full indemnity rights as set forth in the Chemours Separation Agreement. PFAS Matters Historical EID is a party to legal proceedings relating to the use of PFOA and PFCs by its former Performance Chemicals segment. Indemnifiable Losses related to PFAS liabilities allocated to and assumed by Chemours under the Chemours Separation Agreement generally are PFAS Stray Liabilities subject to the sharing arrangement between DuPont and Corteva, described above. Generally, Chemours, with reservations, including as to alleged fraudulent conveyance and voidable transactions, is defending and indemnifying Historical EID in the PFAS Matters discussed below. Although Chemours has refused the tender of the Company’s defense in the actions in which the Company has been named, DuPont believes it is remote that it will ultimately incur a liability in connection with these PFAS Matters. Personal Injury and Other PFAS Actions DuPont, which was formed after the spin-off of Chemours, is not named in the personal injury and other PFAS actions discussed below. Personal Injury In 2004, Historical EID settled a West Virginia state court class action, Leach v. DuPont, which alleged that PFOA from Historical EID’s former Washington Works facility had contaminated area drinking water supplies and affected the health of area residents. Historical EID has residual liabilities under the Leach settlement related to providing PFOA water treatment to six area water districts and private well users and to fund, through an escrow account, up to $235 million for a medical monitoring program for eligible class members. Members of the Leach class have standing to pursue personal injury claims for just six health conditions that an expert panel appointed under the Leach settlement reported in 2012 had a “probable link” (as defined in the settlement) with PFOA: pregnancy-induced hypertension, including preeclampsia; kidney cancer; testicular cancer; thyroid disease; ulcerative colitis; and diagnosed high cholesterol. In 2017, Chemours and Historical EID each paid $335 million to settle the multi-district litigation in the U.S. District Court for the Southern District of Ohio (“Ohio MDL”), thereby resolving claims of about 3,550 plaintiffs alleging injury from exposure to PFOA in drinking water. The 2017 settlement did not resolve claims of Leach class members who did not have claims in the Ohio MDL or whose claims are based on diseases first diagnosed after February 11, 2017. About 80 claims alleging personal injury, including kidney and testicular cancer claims, have been filed since the 2017 settlement. These claims are currently pending in the Ohio MDL. The first two cases, one captioned “Abbott v E. I. du Pont de Nemours and Company” and the other “Swartz v. E. I. du Pont de Nemours and Company”, involving a testicular cancer and a kidney cancer claim, respectively, proceeded to trial in January 2020. In the Abbott case, the jury returned a verdict in March 2020 against Historical EID, awarding $50 million in compensatory damages to the plaintiff and his wife, who claimed that exposure to PFOA in drinking water caused him to develop testicular cancer. Historical EID will appeal the verdict. The plaintiffs also sought but were not awarded punitive damages. In the Swartz matter, the jury could not reach a verdict. Therefore, the court declared a mistrial and the matter will be retried at a later date. The trials in the cases originally scheduled for June 2020 have been postponed to August 2020 due to the COVID-19 pandemic. Natural Resource Damage Claims and Other Claims for Environmental Damages In addition to the actions described above, there are about 100 cases alleging damages to natural resources, the environment and/or property as well as various other allegations. DuPont is named as a defendant in certain of these actions as discussed below. Drinking Water Since May 2017, a number of municipal water districts and state attorneys general have filed lawsuits against Historical EID, Chemours, 3M, and others, claiming contamination of public water systems by certain PFAS compounds. Such actions are currently pending in Ohio, Michigan, New Jersey, New Hampshire, New York, and Vermont. Generally, the states seek economic impact damages for alleged harm to natural resources, punitive damages, and present and future costs to cleanup contamination from certain PFAS compounds and to abate the alleged nuisance. DuPont is a named party in the New Jersey suit related to its site in Parlin, New Jersey. In addition, the New Jersey Attorney General and New Jersey State Department of Environmental Protection filed two directives, one of which names DuPont. The directives seek information on the historical and current use of PFAS. DuPont is also a named party to the Vermont suit and the Michigan suit. The amended complaints in the New Jersey and Vermont cases and the complaint filed by Michigan include additional causes of action based on allegations that the transfer by Historical EID of certain PFAS liabilities to Chemours prior to spinning off Chemours resulted in a fraudulent conveyance or voidable transaction. Lawsuits have been filed by residents and several water districts against Historical EID and Chemours in New York federal and state courts, including a putative class action, alleging exposure to PFOA from third-party defendant manufacturing operations and seeking compensatory, consequential and punitive damages, medical monitoring and attorneys’ fees, expenses and interest. Other PFAS Actions There are several actions pending in federal court against Historical EID and Chemours, relating to discharges of PFCs, including GenX, into the Cape Fear River. GenX is a polymerization processing aid and a replacement for PFOA introduced by Historical EID which Chemours continues to manufacture at its Fayetteville Works facility in Bladen County, North Carolina. One of these actions is a consolidated putative class action that asserts claims for damages and other relief on behalf of putative classes of property owners and residents in areas near or who draw drinking water from the Cape Fear River. Another action is a consolidated action brought by various North Carolina water authorities, including the Cape Fear Public Utility Authority and Brunswick County, that seek actual and punitive damages as well as injunctive relief. In addition, an action is pending in North Carolina state court on behalf of about 100 plaintiffs who own wells and property near the Fayetteville Works facility. The plaintiffs seek damages for nuisance allegedly caused by releases of certain PFCs from the site. Aqueous Film Forming Foam Beginning in April 2019, several dozen lawsuits involving water contamination arising from the use of PFAS-containing aqueous firefighting foams (“AFFF”) were filed against Historical EID, Chemours, 3M and other AFFF manufacturers and in different parts of the country. Most were consolidated in multi-district litigation docket in federal district court in South Carolina (the “SC MDL”). Many of those cases also name DuPont as a defendant. Those actions largely seek remediation of the alleged PFAS contamination in and around military bases and airports as well as medical monitoring of affected residents. As of the latter part of April 2020, approximately 600 personal injury cases have been filed directly in the SC MDL and assert claims on behalf of individual firefighters and others who allege that exposure to PFAS in firefighting foam caused them to develop cancer, including kidney and testicular cancer. DuPont has been named as a defendant in approximately 565 personal injury AFFF cases. DuPont is seeking the dismissal of DowDuPont and DuPont from these actions. Historical EID and the Company have never made or sold aqueous film forming foam, PFOS or PFOS containing products. Additionally, a case filed by a former firefighter is pending in the Southern District of Ohio seeking certification of a nationwide class of individuals who have detectable levels of PFAS in their blood serum. The suit was filed against 3M and several other defendants in addition to Chemours and Historical EID. The complaint specifically seeks, among other things, the creation of a “PFAS Science Panel” to study the effects of PFAS, but expressly states that the class does not seek compensatory damages for personal injuries. In February 2020, the court denied the defendants' motion to transfer this case to the SC MDL. Other Litigation Matters In addition to the specific matters described above, the Company is party to other claims and lawsuits arising out of the normal course of business with respect to product liability, patent infringement, governmental regulation, contract and commercial litigation, and other actions. Certain of these actions may purport to be class actions and seek damages in very large amounts. It is the opinion of the Company’s management that the possibility is remote that the aggregate of all such other claims and lawsuits will have a material adverse impact on the results of operations, financial condition and cash flows of the Company. Environmental Matters Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on current law and existing technologies. At March 31, 2020, the Company had accrued obligations of $77 million for probable environmental remediation and restoration costs, inclusive of $35 million retained and assumed following the Distributions and $42 million of indemnified liabilities. These obligations are included in "Accrued and other current liabilities" and "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheets. This is management’s best estimate of the costs for remediation and restoration with respect to environmental matters for which the Company has accrued liabilities, although it is reasonably possible that the ultimate cost with respect to these particular matters could range up to $171 million above the amount accrued at March 31, 2020. Consequently, it is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the Company’s results of operations, financial condition and cash flows. Inherent uncertainties exist in these estimates primarily due to unknown conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies for handling site remediation and restoration. At December 31, 2019, the Company had accrued obligations of $77 million for probable environmental remediation and restoration costs. Pursuant to the Separation and Distribution Agreement, the Company is required to indemnify certain clean-up responsibilities and associated remediation costs. The accrued environmental obligations of $77 million as of March 31, 2020 includes amount for which the Company indemnifies Dow and Corteva. At March 31, 2020, the Company has indemnified Dow and Corteva $8 million and $34 million , respectively. Guarantees Obligations for Equity Affiliates & Others The Company has directly guaranteed various debt obligations under agreements with third parties related to equity affiliates and customers. At March 31, 2020 and December 31, 2019 , the Company had directly guaranteed $185 million and $187 million , respectively, of such obligations. These amounts represent the maximum potential amount of future (undiscounted) payments that the Company could be required to make under the guarantees. The Company would be required to perform on these guarantees in the event of default by the guaranteed party. The Company assesses the payment/performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used. In certain cases, the Company has recourse to assets held as collateral, as well as personal guarantees from customers. Assuming liquidation, these assets are estimated to cover approximately 10 percent of the $21 million of guaranteed obligations of customers. The following table provides a summary of the final expiration year and maximum future payments for each type of guarantee: Guarantees at March 31, 2020 Final Expiration Year Maximum Future Payments In millions Obligations for customers 1 : Bank borrowings 2020 $ 21 Obligations for non-consolidated affiliates 2 : Bank borrowings 2020 $ 164 Total guarantees $ 185 1. Existing guarantees for select customers, as part of contractual agreements. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance customer invoices. Of the total maximum future payments, $21 million had terms less than a year. 2. Existing guarantees for non-consolidated affiliates' liquidity needs in normal operations.

LEASES (Notes)

LEASES (Notes)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Leases of Lessee Disclosure [Text Block]	OPERATING LEASES Operating lease costs for the three months ended March 31, 2020 and 2019 were $42 million and $44 million , respectively. Operating cash flows from operating leases were $42 million and $41 million for the three months ended March 31, 2020 and 2019, respectively. Operating lease right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. New operating lease assets and liabilities entered into during the three months ended March 31, 2020 were $57 million and immaterial for the three months ended March 31, 2019 . Supplemental balance sheet information related to leases was as follows: In millions March 31, 2020 December 31, 2019 Operating Leases Operating lease right-of-use assets 1 $ 589 $ 556 Current operating lease liabilities 2 143 138 Noncurrent operating lease liabilities 3 444 416 Total operating lease liabilities $ 587 $ 554 1. Included in "Deferred charges and other assets" in the interim Condensed Consolidated Balance Sheet. 2. Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheet. 3. Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheet.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
STOCKHOLDERS' EQUITY AND ACCUMULATED OTHER COMPREHENSIVE LOSS	STOCKHOLDERS' EQUITY Share Repurchase Program On June 1, 2019, the Company's Board of Directors approved a new $2 billion share buyback program, which expires on June 1, 2021. During the first quarter, the Company repurchased and retired 6.1 million shares for $232 million . At March 31, 2020 , the Company had repurchased and retired 16.9 million shares under this program at a total cost of $982 million . Accumulated Other Comprehensive Loss The following table summarizes the activity related to each component of accumulated other comprehensive loss ("AOCL") for the three months ended March 31, 2020 and 2019 : Accumulated Other Comprehensive Loss Unrealized Gains (Losses) on Investments Cumulative Translation Adj Pension and OPEB Derivative Instruments Total In millions 2019 Balance at January 1, 2019 $ (51 ) $ (3,785 ) $ (8,476 ) $ (82 ) $ (12,394 ) Other comprehensive income (loss) before reclassifications 68 (79 ) (7 ) (65 ) (83 ) Amounts reclassified from accumulated other comprehensive loss (1 ) (18 ) 142 (10 ) 113 Net other comprehensive income (loss) $ 67 $ (97 ) $ 135 $ (75 ) $ 30 Balance at March 31, 2019 $ 16 $ (3,882 ) $ (8,341 ) $ (157 ) $ (12,364 ) 2020 Balance at January 1, 2020 $ — $ (1,070 ) $ (345 ) $ (1 ) $ (1,416 ) Other comprehensive loss before reclassifications — (396 ) (2 ) — (398 ) Amounts reclassified from accumulated other comprehensive loss — — 4 — 4 Net other comprehensive (loss) income $ — $ (396 ) $ 2 $ — $ (394 ) Balance at March 31, 2020 $ — $ (1,466 ) $ (343 ) $ (1 ) $ (1,810 ) The tax effects on the net activity related to each component of other comprehensive income (loss) for the three months ended March 31, 2020 and 2019 were as follows: Tax Benefit (Expense) Three Months Ended March 31, In millions 2020 2019 Unrealized gains (losses) on investments $ — $ (18 ) Cumulative translation adjustments — (1 ) Pension and other post employment benefit plans (1 ) (32 ) Derivative instruments — 24 Tax expense from income taxes related to other comprehensive income items $ (1 ) $ (27 ) A summary of the reclassifications out of AOCL for the three months ended March 31, 2020 and 2019 is provided as follows: Reclassifications Out of Accumulated Other Comprehensive Loss Three Months Ended Income Classification In millions 2020 2019 Unrealized gains on investments $ — $ (1 ) See (1) below Tax expense (benefit) — — See (2) below After tax $ — $ (1 ) Cumulative translation adjustments $ — $ (18 ) See (3) below Pension and other post employment benefit plans $ 3 $ 167 See (4) below Tax expense (benefit) 1 (25 ) See (2) below After tax $ 4 $ 142 Derivative Instruments $ — $ (11 ) See (5) below Tax expense — 1 See (2) below After tax $ — $ (10 ) Total reclassifications for the period, after tax $ 4 $ 113 1. "Net sales" and "Sundry income (expense) - net." 2. "Provision for income taxes on continuing operations." 3. "Sundry income (expense) - net." 4. These AOCL components are included in the computation of net periodic benefit cost of the Company's defined benefit pension and other post employment benefit plans. See Note 17 for additional information. 5. "Cost of sales," "Sundry income (expense) - net" and "Interest expense."

NONCONTROLLING INTERESTS

NONCONTROLLING INTERESTS	3 Months Ended
	Mar. 31, 2020
Noncontrolling Interest [Abstract]
NONCONTROLLING INTERESTS	NONCONTROLLING INTERESTS Ownership interests in the Company's subsidiaries held by parties other than the Company are presented separately from the Company's equity in the interim Condensed Consolidated Balance Sheets as "Noncontrolling interests." The amount of consolidated net income attributable to the Company and the noncontrolling interests is both presented on the face of the interim Consolidated Statements of Operations. The following table summarizes the activity for equity attributable to noncontrolling interests for the three months ended March 31, 2020 and 2019 : Noncontrolling Interests Three Months Ended March 31, In millions 2020 2019 Balance at beginning of period $ 569 $ 1,608 Net income attributable to noncontrolling interests 6 51 Distributions to noncontrolling interests (6 ) (11 ) Cumulative translation adjustments (8 ) 7 Other 5 (1 ) Balance at end of period $ 566 $ 1,654

PENSION PLANS AND OTHER POSTRET

PENSION PLANS AND OTHER POSTRETIREMENT BENEFITS	3 Months Ended
	Mar. 31, 2020
Retirement Benefits [Abstract]
PENSION PLANS AND OTHER POSTRETIREMENT BENEFITS	PENSION PLANS AND OTHER POST EMPLOYMENT BENEFITS A summary of the Company's pension plans and other post employment benefits can be found in Note 20 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 . Historical Dow and Historical EID did not merge their defined benefit pension and other post employment benefit plans as a result of the Merger. The following sets forth the components of the Company's net periodic benefit (credit) cost for defined benefit pension plans and other post employment benefits: Net Periodic Benefit (Credit) Cost for All Plans Three Months Ended March 31, In millions 2020 2019 Defined Benefit Pension Plans: Service cost 1 $ 18 $ 131 Interest cost 2 14 447 Expected return on plan assets 3 (28 ) (713 ) Amortization of prior service credit 4 (1 ) (6 ) Amortization of net loss 5 4 133 Net periodic benefit (credit) cost - total $ 7 $ (8 ) Less: Net periodic benefit (credit) cost - discontinued operations — (4 ) Net periodic benefit credit - continuing operations $ 7 $ (4 ) Other Post Employment Benefits: Service cost 1 $ — $ 4 Interest cost 2 — 37 Amortization of net gain 5 — (6 ) Net periodic benefit cost - total $ — $ 35 Less: Net periodic benefit (credit) cost - discontinued operations — 34 Net periodic benefit cost - continuing operations $ — $ 1 1. The service cost from continuing operations was $16 million for the three months ended March 31, 2019. The activity from OPEBs was immaterial. 2. The interest cost from continuing operations was $21 million for the three months ended March 31, 2019. The activity from OPEBs was immaterial. 3. The expected return on plan assets from continuing operations was $43 million for the three months ended March 31, 2019. The activity from OPEBs was immaterial. 4. The amortization of prior service credit from continuing operations was immaterial for the three months ended March 31, 2019 for both pensions and OPEBs. 5. The amortization of unrecognized net loss from continuing operations was $2 million for the three months ended March 31, 2019. The activity from OPEBs was immaterial. The continuing operations portion of the net periodic benefit (credit) cost, other than the service cost component, is included in "Sundry income (expense) - net" in the interim Consolidated Statements of Operations. DuPont expects to make additional contributions in the aggregate of approximately $60 million by year-end 2020 .

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Share-based Payment Arrangement [Text Block]	STOCK-BASED COMPENSATION A summary of the Historical Dow and Historical DuPont stock-based compensation plans can be found in Note 21 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 . Historical Dow and Historical EID did not merge their equity incentive plans as a result of the Merger. The Historical Dow and Historical EID stock-based compensation plans were assumed by the Company and remained in place with the ability to grant and issue DowDuPont common stock until the Distributions. Immediately following the Corteva Distribution, DuPont adopted the DuPont Omnibus Incentive Plan ("DuPont OIP") which provides for equity-based and cash incentive awards to certain employees, directors, independent contractors and consultants in the form of stock options, restricted stock units ("RSUs") and performance-based restricted stock units ("PSUs"). Upon adoption of the DuPont OIP, the Historical Dow and Historical EID plans were maintained and rolled into the DuPont OIP as separate subplans. The equity awards under these subplans have the same terms and conditions that were applicable to the awards under the Historical Dow and Historical EID plans immediately prior to the Distributions. All new awards will be granted by the OIP. Under the DuPont OIP, a maximum of 10 million shares of common stock are available for award as of March 31, 2020 . DuPont recognized share-based compensation expense in continuing operations of $41 million and $21 million for the three months ended March 31, 2020 and 2019, respectively. The income tax benefits related to stock-based compensation arrangements were $9 million and $4 million for the three months ended March 31, 2020 and 2019 , respectively. In the first quarter of 2020 , the Company granted 1.0 million RSUs, 0.8 million stock options and 0.3 million PSUs. The weighted-average fair values per share associated with the grants were $53.49 per RSU, $8.84 per stock option and $50.23 per PSU. The stock options had a weighted-average exercise price per share of $53.50 .

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	3 Months Ended
	Mar. 31, 2020
Investments, All Other Investments [Abstract]
FINANCIAL INSTRUMENTS	FINANCIAL INSTRUMENTS The following table summarizes the fair value of financial instruments at March 31, 2020 and December 31, 2019 : Fair Value of Financial Instruments March 31, 2020 December 31, 2019 In millions Cost Gain Loss Fair Value Cost Gain Loss Fair Value Cash equivalents $ 771 $ — $ — $ 771 $ 417 $ — $ — $ 417 Restricted cash equivalents 1 $ 34 $ — $ — $ 34 $ 37 $ — $ — $ 37 Total cash and restricted cash equivalents $ 805 $ — $ — $ 805 $ 454 $ — $ — $ 454 Long-term debt including debt due within one year $ (15,620 ) $ 38 $ (1,209 ) $ (16,791 ) $ (15,618 ) $ — $ (1,633 ) $ (17,251 ) Derivatives relating to: Foreign currency 2 — 12 (11 ) 1 — 6 (7 ) (1 ) Total derivatives $ — $ 12 $ (11 ) $ 1 $ — $ 6 $ (7 ) $ (1 ) 1. Classified as "Other current assets" in the interim Condensed Consolidated Balance Sheets. 2. Presented net of cash collateral where master netting arrangements allow. Derivative Instruments Objectives and Strategies for Holding Derivative Instruments In the ordinary course of business, the Company enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency, interest rate and commodity price risks. The Company has established a variety of derivative programs to be utilized for financial risk management. These programs reflect varying levels of exposure coverage and time horizons based on an assessment of risk. Derivative programs have procedures and controls and are approved by the Corporate Financial Risk Management Committee, consistent with the Company's financial risk management policies and guidelines. Derivative instruments used are forwards, options, futures and swaps. As of the first quarter of 2020, the Company has not designated any derivatives or non-derivatives as hedging instruments. The Company's financial risk management procedures also address counterparty credit approval, limits and routine exposure monitoring and reporting. The counterparties to these contractual arrangements are major financial institutions and major commodity exchanges. The Company is exposed to credit loss in the event of nonperformance by these counterparties. The Company utilizes collateral support annex agreements with certain counterparties to limit its exposure to credit losses. The Company anticipates performance by counterparties to these contracts and therefore no material loss is expected. Market and counterparty credit risks associated with these instruments are regularly reported to management. The notional amounts of the Company's derivative instruments were as follows: Notional Amounts March 31, 2020 Dec 31, 2019 In millions Derivatives not designated as hedging instruments: Foreign currency contracts 1 $ (344 ) $ 26 Commodity contracts $ 12 $ 11 1. Presented net of contracts bought and sold. Derivatives not Designated in Hedging Relationships Foreign Currency Contracts The Company routinely uses forward exchange contracts to reduce its net exposure, by currency, related to foreign currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. The netting of such exposures precludes the use of hedge accounting; however, the required revaluation of the forward contracts and the associated foreign currency-denominated monetary assets and liabilities intends to achieve a minimal earnings impact, after taxes. The Company may use foreign currency exchange contracts to offset a portion of the Company's exposure to certain foreign currency-denominated revenues so that gains and losses on the contracts offset changes in the USD value of the related foreign currency-denominated revenues. Commodity Contracts The Company utilizes options, futures and swaps that are not designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of inventory such as soybeans, soybean oil and soybean meal. Fair Value of Derivative Instruments Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the interim Condensed Consolidated Balance Sheets. The presentation of the Company's derivative assets and liabilities is as follows: March 31, 2020 In millions Balance Sheet Classification Gross Counterparty and Cash Collateral Netting 1 Net Amounts Included in the Consolidated Balance Sheet Asset derivatives: Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets $ 34 $ (22 ) $ 12 Total asset derivatives $ 34 $ (22 ) $ 12 Liability derivatives: Derivatives not designated as hedging instruments: Foreign currency contracts Accrued and other current liabilities $ 33 $ (22 ) $ 11 Total liability derivatives $ 33 $ (22 ) $ 11 December 31, 2019 In millions Balance Sheet Classification Gross Counterparty and Cash Collateral Netting 1 Net Amounts Included in the Consolidated Balance Sheet Asset derivatives: Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets $ 16 $ (10 ) $ 6 Total asset derivatives $ 16 $ (10 ) $ 6 Liability derivatives: Derivatives not designated as hedging instruments: Foreign currency contracts Accrued and other current liabilities $ 17 $ (10 ) $ 7 Total liability derivatives $ 17 $ (10 ) $ 7 1. Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the Company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty. Effect of Derivative Instruments Foreign currency derivatives not designated as hedges are used to offset foreign exchange gains or losses resulting from the underlying exposures of foreign currency-denominated assets and liabilities. The amount charged on a pre-tax basis related to foreign currency derivatives not designated as a hedge, which was included in “Sundry income (expense) - net” in the interim Consolidated Statements of Operations, was a gain of $4 million for the three months ended March 31, 2020 ( $47 million loss for the months ended March 31, 2019 ). The income statement effects of other derivatives were immaterial. Reclassification from AOCL The Company does not expect to reclassify gains or losses related to foreign currency contracts from AOCL to income within the next 12 months and there are currently no such amounts included within AOCL.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Fair Value Measurements on a Recurring Basis The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis: Basis of Fair Value Measurements on a Recurring Basis at March 31, 2020 Significant Other Observable Inputs (Level 2) In millions Assets at fair value: Cash equivalents and restricted cash equivalents 1 $ 805 Derivatives relating to: 2 Foreign currency contracts 34 Total assets at fair value $ 839 Liabilities at fair value: Long-term debt including debt due within one year 3 $ 16,791 Derivatives relating to: 2 Foreign currency contracts 33 Total liabilities at fair value $ 16,824 1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value. 2. See Note 19 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets. 3. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms. Basis of Fair Value Measurements on a Recurring Basis at December 31, 2019 Significant Other Observable Inputs (Level 2) In millions Assets at fair value: Cash equivalents and restricted cash equivalents 1 $ 454 Derivatives relating to: 2 Foreign currency contracts 16 Total assets at fair value $ 470 Liabilities at fair value: Long-term debt including debt due within one year 3 $ 17,251 Derivatives relating to: 2 Foreign currency contracts 17 Total liabilities at fair value $ 17,268 1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value. 2. See Note 19 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets 3. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms. Fair Value Measurements on a Nonrecurring Basis During the first quarter of 2020, the Company recorded impairment charges related to goodwill and long-lived assets within the Non-Core segment. See Notes 11 and 5 for further discussion of these fair value measurements.

SEGMENTS AND GEOGRAPHIC REGIONS

SEGMENTS AND GEOGRAPHIC REGIONS	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
SEGMENTS AND GEOGRAPHIC REGIONS	SEGMENTS AND GEOGRAPHIC REGIONS In the first quarter of 2020, in preparation for the Proposed N&B Transaction, DuPont changed its management and reporting structure to realign costs associated with its polysaccharides pre-commercial activities from the Non-Core segment to the N&B segment. The reporting changes have been retrospectively reflected in the segment results for all periods presented. Prior to April 1, 2019, the Company's measure of profit / loss for segment reporting purposes is pro forma Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assessed performance and allocates resources. The Company defines pro forma Operating EBITDA as pro forma earnings (i.e. pro forma "Income (loss) from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / other post employment benefits (“OPEB”) / charges, and foreign exchange gains/losses, excluding the impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations and adjusted for significant items. Effective April 1, 2019, the Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, adjusted for significant items. Reconciliations of these measures are provided on the following pages. Pro forma adjustments were determined in accordance with Article 11 of Regulation S-X. Pro forma financial information is based on the Consolidated Financial Statements of DuPont, adjusted to give effect to the impact of certain items directly attributable to the Distributions, and the Term Loan Facilities, the 2018 Senior Notes and the Funding CP Issuance (together, the "Financings"), including the use of proceeds from such Financings (collectively the "Transactions"). The historical consolidated financial information has been adjusted to give effect to pro forma events that are (1) directly attributable to the Transactions, (2) factually supportable and (3) with respect to the statements of operations, expected to have a continuing impact on the results. Events that are not expected to have a continuing impact on the combined results are excluded from the pro forma adjustments. Those pro forma adjustments include the impact of various supply agreements entered into in connection with the Dow Distribution ("supply agreements") and are adjustments to "Cost of sales." Pro forma Operating EBITDA for the three months ended March 31, 2019 has been adjusted to reflect the supply agreements if they had been effective January 1, 2018 as they are included in the measure of profit/loss reviewed by the CODM in order to show meaningful comparability among periods while assessing performance and making resource allocation decisions. There were no pro forma adjustments for the three months ended March 31, 2020 . Segment Information Elect. & Imaging Nutrition & Biosciences Transp. & Industrial Safety & Const. Non-Core Corp. Total In millions Three Months Ended March 31, 2020 Net sales $ 884 $ 1,551 $ 1,144 $ 1,276 $ 366 $ — $ 5,221 Operating EBITDA 1 $ 253 $ 385 $ 308 $ 368 $ 42 $ (35 ) $ 1,321 Equity in earnings of nonconsolidated affiliates $ 9 $ — $ 1 $ 7 $ 22 $ — $ 39 Three months ended March 31, 2019 Net sales $ 825 $ 1,535 $ 1,317 $ 1,283 $ 454 $ — $ 5,414 Pro forma operating EBITDA 1 $ 288 $ 349 $ 373 $ 374 $ 98 $ (52 ) $ 1,430 Equity in earnings of nonconsolidated affiliates 2 $ 3 $ — $ — $ 8 $ 30 $ — $ 41 1. A reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA and pro forma Operating EBITDA, as applicable, is provided below. 2. Represents equity in earnings (losses) of nonconsolidated affiliates included in pro forma Operating EBITDA, the Company's measure of profit/loss for segment reporting purposes, which excludes significant items. Accordingly, the Non-Core segment presented above excludes a restructuring charge of $1 million which is presented in "Equity in earnings of nonconsolidated affiliates" in the Company's interim Consolidated Statement of Operations. Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Three Months Ended March 31, 2020 and 2019 Three Months Ended March 31, In millions 2020 2019 Loss from continuing operations, net of tax $ (610 ) $ (74 ) + Provision for (benefit from) income taxes on continuing operations 44 (91 ) Loss from continuing operations before income taxes $ (566 ) $ (165 ) + Pro forma adjustments 1 — 122 + Depreciation and amortization 772 527 - Interest income 2 2 40 + Interest expense 3 173 180 - Non-operating pension/OPEB benefit 2 11 21 - Foreign exchange gains (losses), net 2 (8 ) (61 ) + Costs historically allocated to the materials science and agriculture businesses 4 — 256 - Significant items 5 (947 ) (510 ) Operating EBITDA 1 $ 1,321 $ 1,430 1. For the three months ended March 31, 2019 , operating EBITDA is on a pro forma basis. The pro forma adjustment reflects the net pro forma impact of items directly attributable to the Transactions, as applicable. 2. Included in "Sundry income (expense) - net." 3. The three months ended March 31, 2020 excludes N&B financing fee amortization. Refer to details of significant items below. 4. Costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205. 5. The significant items for the three months ended March 31, 2020, are presented on an as reported basis. The adjusted significant items for the three months ended March 31, 2019 are presented on a pro forma basis. The significant items for the three months ended March 31, 2020 , are presented on an as reported basis. The adjusted significant items for the three months ended March 31, 2019 are presented on a pro forma basis. The following tables summarize the pre-tax impact of significant items by segment that are excluded from Operating EBITDA and pro forma Operating EBITDA above: Significant Items by Segment for the Three Months Ended March 31, 2020 Elect. & Imaging Nutrition & Biosciences Transp. & Industrial Safety & Construction Non-Core Corporate Total In millions Integration and separation costs 1 $ — $ — $ — $ — $ — $ (197 ) $ (197 ) Restructuring and asset related charges - net 2 (4 ) (6 ) (25 ) (25 ) — (74 ) (134 ) Goodwill impairment charge 3 — — — — (533 ) — (533 ) Asset impairment charges 4 — — — — (270 ) — (270 ) Gain on divestiture 5 197 — — — — — 197 N&B financing fee amortization 6 — — — — — (10 ) (10 ) Total $ 193 $ (6 ) $ (25 ) $ (25 ) $ (803 ) $ (281 ) $ (947 ) 1. Integration and separation costs related to the post-Merger integration and the intended separation of the N&B Business. 2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information. 3. See Note 11 for additional information. 4. See Note 5 for additional information. 5. Reflected in "Sundry income (expense) - net." Refer to Note 3 for additional information. 6. Reflected in "Interest expense" and relates to the intended separation of the N&B Business. Adjusted Significant Items by Segment for the Three Months Ended March 31, 2019 (Pro Forma) Elect. & Imaging Nutrition & Biosciences Transp. & Industrial Safety & Construction Non-Core Corporate Total In millions Integration and separation costs 1 — — — — — $ (438 ) $ (438 ) Restructuring and asset related charges - net 2 — (27 ) — (2 ) 1 (44 ) (72 ) Total $ — $ (27 ) $ — $ (2 ) $ 1 $ (482 ) $ (510 ) 1. Integration and separation costs related to the Merger, post-Merger integration and business separation activities. 2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Interim Financial Statements The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the interim statements reflect all adjustments (including normal recurring accruals) which are considered necessary for the fair statement of the results for the periods presented. Results from interim periods should not be considered indicative of results for the full year. These interim Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, collectively referred to as the “2019 Annual Report.” The interim Consolidated Financial Statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained.
Basis of Presentation and Significant Accounting Policies [Text Block]	Basis of Presentation Effective August 31, 2017, pursuant to the merger of equals transaction contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 ("Merger Agreement"), The Dow Chemical Company ("Historical Dow") and E. I. du Pont de Nemours and Company ("Historical EID") each merged with subsidiaries of DowDuPont Inc. ("DowDuPont") and, as a result, Historical Dow and Historical EID became subsidiaries of DowDuPont (the "Merger"). Prior to the Merger, DowDuPont did not conduct any business activities other than those required for its formation and matters contemplated by the Merger Agreement. Historical Dow was determined to be the accounting acquirer in the Merger.
Discontinued Operations, Policy [Policy Text Block]	Effective as of 5:00 p.m. on April 1, 2019, the Company completed the separation of its materials science business into a separate and independent public company by way of a distribution of Dow Inc. (“Dow”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock (the “Dow Common Stock”), to holders of the Company’s common stock (the “DowDuPont common stock”), as of the close of business on March 21, 2019 (the “Dow Distribution”). Effective as of 12:01 a.m. on June 1, 2019, the Company completed the separation of its agriculture business into a separate and independent public company by way of a distribution of Corteva, Inc. (“Corteva”) through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Corteva’s common stock (the “Corteva Common Stock”), to holders of the Company’s common stock as of the close of business on May 24, 2019 (the “Corteva Distribution” and, together with the Dow Distribution, the “Distributions”). Following the Corteva Distribution, DuPont holds the specialty products business. On June 1, 2019, DowDuPont changed its registered name from "DowDuPont Inc." to "DuPont de Nemours, Inc." doing business as "DuPont." Beginning on June 3, 2019, the Company's common stock is traded on the NYSE under the ticker symbol "DD". The results of operations of DuPont for the three months ended March 31, 2019 present the historical financial results of Dow and Corteva as discontinued operations. The cash flows and comprehensive income related to Dow and Corteva have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for the applicable period. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of Dow or Corteva. On December 15, 2019, the Company entered into definitive agreements to separate and combine the Nutrition & Biosciences business segment (the "N&B Business") with International Flavors & Fragrances Inc. ("IFF") in a tax-efficient Reverse Morris Trust transaction, (the "Proposed N&B Transaction"). The transaction is expected to close by the end of the first quarter of 2021, subject to approval by IFF shareholders and other customary closing conditions, including regulatory approvals and receipt by

RECENT ACCOUNTING GUIDANCE (Pol

RECENT ACCOUNTING GUIDANCE (Policies)	3 Months Ended
	Mar. 31, 2020
Recent Accounting Guidance [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Guidance In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and associated ASUs related to Topic 326. The new guidance introduces the current expected credit loss (“CECL”) model, which requires organizations to record an allowance for credit losses for certain financial instruments and financial assets, including trade receivables, based on expected losses rather than incurred losses. Under this update, on initial recognition and at each reporting period, an entity will be required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. This update became effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the new standard in the first quarter of 2020, which required a modified retrospective transition approach, applying the new standard's cumulative-effect adjustment at the date of initial adoption. This cumulative-effect has been reflected as of January 1, 2020 and prior periods have not been restated. The impact of initial adoption was not material to the Company’s interim Condensed Consolidated Balance Sheet, interim Consolidated Statements of Operations, and interim Consolidated Statement of Cash Flows.

DIVESTITURES (Tables)

DIVESTITURES (Tables)	3 Months Ended
	Mar. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Integration and Separation Costs [Table Text Block]	Three Months Ended March 31, In millions 2020 2019 Integration and separation costs $ 197 $ 611
Materials Science Division [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Groups, Including Discontinued Operations [Table Text Block]	The results of operations of the Materials Science Division are presented as discontinued operations as summarized below: Three Months Ended In millions Net sales $ 10,867 Cost of sales 8,917 Research and development expenses 163 Selling, general and administrative expenses 329 Amortization of intangibles 116 Restructuring and asset related charges - net 157 Integration and separation costs 44 Equity in earnings of nonconsolidated affiliates (13 ) Sundry income (expense) - net 99 Interest expense 240 Income from discontinued operations before income taxes 987 Provision for income taxes on discontinued operations 261 Income from discontinued operations, net of tax 726 Income from discontinued operations attributable to noncontrolling interests, net of tax 37 Income from discontinued operations attributable to DuPont stockholders, net of tax $ 689 The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the Materials Science Division: Three Months Ended In millions Depreciation and amortization $ 744 Capital expenditures $ 597
Agriculture Division [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Groups, Including Discontinued Operations [Table Text Block]	The results of operations of the Agriculture Division are presented as discontinued operations as summarized below: Three Months Ended In millions Net sales $ 3,368 Cost of sales 2,192 Research and development expenses 287 Selling, general and administrative expenses 617 Amortization of intangibles 102 Restructuring and asset related charges - net 59 Integration and separation costs 158 Equity in earnings of nonconsolidated affiliates (1 ) Sundry income (expense) - net 65 Interest expense 63 Income from discontinued operations before income taxes (46 ) Provision for income taxes on discontinued operations 34 Income from discontinued operations, net of tax (80 ) Income from discontinued operations attributable to noncontrolling interests, net of tax 10 Income from discontinued operations attributable to DuPont stockholders, net of tax $ (90 ) The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to the Agriculture Division: Three Months Ended In millions Depreciation and amortization $ 249 Capital expenditures $ 222

REVENUE (Tables)

REVENUE (Tables)	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	Net Trade Revenue by Segment and Business or Major Product Line Three Months Ended March 31, In millions 2020 2019 Image Solutions $ 148 $ 154 Interconnect Solutions 266 238 Semiconductor Technologies 470 433 Electronics & Imaging $ 884 $ 825 Food & Beverage $ 738 $ 755 Health & Biosciences 605 570 Pharma Solutions 208 210 Nutrition & Biosciences $ 1,551 $ 1,535 Healthcare & Specialty $ 359 $ 384 Industrial & Consumer 266 308 Mobility Solutions 519 625 Transportation & Industrial $ 1,144 $ 1,317 Safety Solutions $ 631 $ 665 Shelter Solutions 348 357 Water Solutions 297 261 Safety & Construction $ 1,276 $ 1,283 Biomaterials $ 34 $ 59 Clean Technologies 60 65 DuPont Teijin Films 43 37 Photovoltaic & Advanced Materials 229 254 Sustainable Solutions 1 — 39 Non-Core $ 366 $ 454 Total $ 5,221 $ 5,414 1. The Sustainable Solutions business was divested in the third quarter of 2019. Net Trade Revenue by Geographic Region Three Months Ended March 31, In millions 2020 2019 U.S. & Canada $ 1,742 $ 1,776 EMEA 1 1,271 1,380 Asia Pacific 1,913 1,945 Latin America 295 313 Total $ 5,221 $ 5,414 1. Europe, Middle East and Africa.
Contract with Customer, Asset and Liability [Table Text Block]	Contract Balances March 31, 2020 December 31, 2019 In millions Accounts and notes receivable - trade 1 $ 3,156 $ 3,007 Contract assets - current 2 $ 32 $ 35 Deferred revenue - current 3 $ 69 $ 43 Deferred revenue - noncurrent 4 $ 29 $ 34 1. Included in "Accounts and notes receivable - net" in the interim Condensed Consolidated Balance Sheets. 2. Included in "Other current assets" in the interim Condensed Consolidated Balance Sheets. 3. Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets. 4. Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheets.

RESTRUCTURING AND ASSET RELAT_2

RESTRUCTURING AND ASSET RELATED CHARGES - NET (Tables)	3 Months Ended
	Mar. 31, 2020
2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	The following table summarizes the charges incurred by segment related to the 2020 Restructuring Program: 2020 Restructuring Program Charges by Segment Three Months Ended March 31, 2020 In millions Electronics & Imaging $ 4 Nutrition & Biosciences 6 Transportation & Industrial 24 Safety & Construction 20 Non-Core — Corporate 57 Total $ 111
2019 Restructuring Program [Domain]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the activities related to the 2019 Restructuring Program: 2019 Restructuring Program Severance and Related Benefit Costs In millions Reserve balance at December 31, 2019 $ 86 Current quarter restructuring charges 18 Non-cash compensation (6 ) Cash payments (23 ) Reserve balance at March 31, 2020 $ 75
DowDuPont Cost Synergy Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	The following tables summarize the charges incurred related to the DowDuPont Cost Synergy Program: Three Months Ended March 31, In millions 2020 2019 Severance and related benefit costs $ — $ 43 Contract termination charges 5 16 Asset related charges — 13 Total restructuring and asset related charges - net 1,2 $ 5 $ 72 1. The charges for the three months ended March 31, 2020 include $5 million related to Safety and Construction. 2. The charges for the three months ended March 31, 2019 include $27 million related to Nutrition & Biosciences, $2 million related to Safety and Construction, $44 million related to Corporate, and a benefit of $1 million related to Non Core.
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the activities related to the DowDuPont Cost Synergy Program: DowDuPont Cost Synergy Program Severance and Related Benefit Costs Contract Termination Charges Total In millions Reserve balance at December 31, 2019 $ 74 $ 2 $ 76 Current quarter restructuring charges — 5 5 Cash payments (22 ) — (22 ) Reserve balance at March 31, 2020 $ 52 $ 7 $ 59

SUPPLEMENTARY INFORMATION (Tabl

SUPPLEMENTARY INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of sundry income (expense), net	Sundry Income (Expense) - Net Three Months Ended March 31, In millions 2020 2019 Non-operating pension and other post employment benefit (OPEB) credits $ 11 $ 21 Interest income 2 40 Net gain on divestiture and sales of other assets and investments 1,2 197 53 Foreign exchange (losses) gains, net (8 ) (61 ) Miscellaneous income (expenses) - net 3 9 31 Sundry income (expense) - net $ 211 $ 84 1. The three months ended March 31, 2020 reflects income of $197 million related to the gain on sale of the Compound Semiconductor Solutions business unit within the Electronics & Imaging segment. 2. The three months ended March 31, 2019 includes income of $51 million related to a sale of assets within the Electronics & Imaging segment. 3. Miscellaneous income (expenses) - net for the three months ended March 31, 2019 includes $26 million related to licensing income within the Safety & Construction segment.

EARNINGS PER SHARE CALCULATIO_2

EARNINGS PER SHARE CALCULATIONS (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Schedule of Earnings Per Share	The following tables provide earnings per share calculations for the three months ended March 31, 2020 and 2019 : Net Income for Earnings Per Share Calculations - Basic & Diluted Three Months Ended March 31, In millions 2020 2019 Loss from continuing operations, net of tax $ (610 ) $ (74 ) Net income from continuing operations attributable to noncontrolling interests 6 4 Net income from continuing operations attributable to participating securities 1 — 1 Loss from continuing operations attributable to common stockholders $ (616 ) $ (79 ) Income from discontinued operations, net of tax — 646 Net income from discontinued operations attributable to noncontrolling interests — 47 Income from discontinued operations attributable to common stockholders — 599 Net (loss) income attributable to common stockholders $ (616 ) $ 520 Earnings Per Share Calculations - Basic Three Months Ended March 31, Dollars per share 2020 2019 Loss from continuing operations attributable to common stockholders $ (0.83 ) $ (0.11 ) Income from discontinued operations, net of tax — 0.80 Net (loss) income attributable to common stockholders $ (0.83 ) $ 0.69 Earnings Per Share Calculations - Diluted Three Months Ended March 31, Dollars per share 2020 2019 Loss from continuing operations attributable to common stockholders $ (0.83 ) $ (0.11 ) Income from discontinued operations, net of tax — 0.80 Net (loss) income attributable to common stockholders $ (0.83 ) $ 0.69 Share Count Information Three Months Ended March 31, Shares in millions 2020 2019 Weighted-average common shares - basic 738.6 750.0 Plus dilutive effect of equity compensation plans — — Weighted-average common shares - diluted 738.6 750.0 Stock options and restricted stock units excluded from EPS calculations 2 6.4 6.4 1. Historical Dow restricted stock units are considered participating securities due to Historical Dow's practice of paying dividend equivalents on unvested shares. 2. These outstanding options to purchase shares of common stock and restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive.

INVENTORIES Inventories (Tables

INVENTORIES Inventories (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories March 31, 2020 December 31, 2019 In millions Finished goods $ 2,731 $ 2,621 Work in process 858 855 Raw materials 589 599 Supplies 232 244 Total inventories $ 4,410 $ 4,319

NONCONSOLIDATED AFFILIATES (Tab

NONCONSOLIDATED AFFILIATES (Tables)	3 Months Ended
	Mar. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Nonconsolidated Affiliates - Investments [Table Text Block]	The Company's investments in companies accounted for using the equity method ("nonconsolidated affiliates"), by classification in the interim Condensed Consolidated Balance Sheets, are shown in the following table: Investments in Nonconsolidated Affiliates Mar 31, 2020 Dec 31, 2019 In millions Investments in nonconsolidated affiliates $ 1,227 $ 1,204 Accrued and other current liabilities (84 ) (85 ) Other noncurrent obligations (351 ) (358 ) Net investment in nonconsolidated affiliates $ 792 $ 761
Equity Method Investments [Table Text Block]	The following table reflects the carrying value of the HSC Group investments at March 31, 2020 and December 31, 2019 : Investment in the HSC Group Investment In millions Balance Sheet Classification Mar 31, 2020 Dec 31, 2019 Hemlock Semiconductor L.L.C. Other noncurrent obligations $ (351 ) $ (358 ) DC HSC Holdings LLC Investments in nonconsolidated affiliates $ 97 $ 87 The following is summarized financial information for the Company's principal nonconsolidated equity method investments. The amounts shown below represent 100 percent of these equity method investments' results of operations: Results of Operations Three Months Ended March 31, In millions 2020 2019 Revenues 1 $ 185 $ 185 Cost of sales 1 $ 127 $ 107 Income from continuing operations $ 40 $ 63 Net income attributed to entities $ 35 $ 52 1. Includes sales and cost of sales of $22 million and $21 million for the three months ended March 31, 2020 and 2019, respectively, that have not been eliminated between Hemlock Semiconductor L.L.C and DC HSC Holdings in the presentation of the summarized income statement information above. March 31, 2020 : Country Ownership Interest March 31, 2020 The HSC Group: DC HSC Holdings LLC 1 United States 50.0 % Hemlock Semiconductor L.L.C. United States 50.1 % 1. DC HSC Holdings LLC holds an 80.5 percent indirect ownership interest in Hemlock Semiconductor Operations LLC.

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	Elect. & Imaging Nutrition & Biosciences Transp. & Industrial Safety & Const. Non-Core Total In millions Balance at December 31, 2019 $ 7,092 $ 11,012 $ 6,931 $ 6,711 $ 1,405 $ 33,151 Acquisitions — — — 53 — 53 Divestitures (199 ) — — — — (199 ) Impairments — — — — (533 ) (533 ) Currency Translation Adjustment (11 ) (111 ) (25 ) (26 ) — (173 ) Measurement Period Adjustments — — — 18 — 18 Balance at March 31, 2020 $ 6,882 $ 10,901 $ 6,906 $ 6,756 $ 872 $ 32,317
Schedule of other finite intangible assets	The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows: March 31, 2020 December 31, 2019 In millions Gross Carrying Amount Accum Amort Net Gross Carrying Amount Accum Amort Net Intangible assets with finite lives: Developed technology $ 4,356 $ (1,523 ) $ 2,833 $ 4,343 $ (1,361 ) $ 2,982 Trademarks/tradenames 2,416 (755 ) 1,661 2,433 (455 ) 1,978 Customer-related 8,920 (2,339 ) 6,581 8,986 (2,229 ) 6,757 Other 300 (214 ) 86 303 (98 ) 205 Total other intangible assets with finite lives $ 15,992 $ (4,831 ) $ 11,161 $ 16,065 $ (4,143 ) $ 11,922 Intangible assets with indefinite lives: Trademarks/tradenames 1,673 — 1,673 1,671 — 1,671 Total other intangible assets 1,673 — 1,673 1,671 — 1,671 Total $ 17,665 $ (4,831 ) $ 12,834 $ 17,736 $ (4,143 ) $ 13,593
Schedule of other indefinite intangible assets	The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows: March 31, 2020 December 31, 2019 In millions Gross Carrying Amount Accum Amort Net Gross Carrying Amount Accum Amort Net Intangible assets with finite lives: Developed technology $ 4,356 $ (1,523 ) $ 2,833 $ 4,343 $ (1,361 ) $ 2,982 Trademarks/tradenames 2,416 (755 ) 1,661 2,433 (455 ) 1,978 Customer-related 8,920 (2,339 ) 6,581 8,986 (2,229 ) 6,757 Other 300 (214 ) 86 303 (98 ) 205 Total other intangible assets with finite lives $ 15,992 $ (4,831 ) $ 11,161 $ 16,065 $ (4,143 ) $ 11,922 Intangible assets with indefinite lives: Trademarks/tradenames 1,673 — 1,673 1,671 — 1,671 Total other intangible assets 1,673 — 1,673 1,671 — 1,671 Total $ 17,665 $ (4,831 ) $ 12,834 $ 17,736 $ (4,143 ) $ 13,593
Intangible Assets Disclosure	The following table provides the net carrying value of other intangible assets by segment: Net Intangibles by Segment Mar 31, 2020 Dec 31, 2019 In millions Electronics & Imaging $ 1,764 $ 1,833 Nutrition & Biosciences 3,989 4,377 Transportation & Industrial 3,524 3,590 Safety & Construction 3,048 3,082 Non-Core 509 711 Total $ 12,834 $ 13,593
Schedule of amortization expense	The following table provides information regarding amortization expense related to other intangible assets: Amortization Expense Three Months Ended March 31, In millions 2020 2019 Other intangible assets $ 533 $ 256
Schedule of estimated future amortization expense	Total estimated amortization expense for the remainder of 2020 and the five succeeding fiscal years is as follows: Estimated Amortization Expense In millions 2020 $ 1,595 2021 $ 1,008 2022 $ 968 2023 $ 925 2024 $ 826 2025 $ 789

COMMITMENTS AND CONTINGENT LI_2

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Guarantor Obligations	The following table provides a summary of the final expiration year and maximum future payments for each type of guarantee: Guarantees at March 31, 2020 Final Expiration Year Maximum Future Payments In millions Obligations for customers 1 : Bank borrowings 2020 $ 21 Obligations for non-consolidated affiliates 2 : Bank borrowings 2020 $ 164 Total guarantees $ 185 1. Existing guarantees for select customers, as part of contractual agreements. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance customer invoices. Of the total maximum future payments, $21 million had terms less than a year. 2. Existing guarantees for non-consolidated affiliates' liquidity needs in normal operations.

LEASES Schedule of Leases (Tabl

LEASES Schedule of Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Schedule of Lease Assets and Liabilities [Table Text Block]	Supplemental balance sheet information related to leases was as follows: In millions March 31, 2020 December 31, 2019 Operating Leases Operating lease right-of-use assets 1 $ 589 $ 556 Current operating lease liabilities 2 143 138 Noncurrent operating lease liabilities 3 444 416 Total operating lease liabilities $ 587 $ 554 1. Included in "Deferred charges and other assets" in the interim Condensed Consolidated Balance Sheet. 2. Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheet. 3. Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheet.

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of Components of Other Comprehensive Income (Loss)	The following table summarizes the activity related to each component of accumulated other comprehensive loss ("AOCL") for the three months ended March 31, 2020 and 2019 : Accumulated Other Comprehensive Loss Unrealized Gains (Losses) on Investments Cumulative Translation Adj Pension and OPEB Derivative Instruments Total In millions 2019 Balance at January 1, 2019 $ (51 ) $ (3,785 ) $ (8,476 ) $ (82 ) $ (12,394 ) Other comprehensive income (loss) before reclassifications 68 (79 ) (7 ) (65 ) (83 ) Amounts reclassified from accumulated other comprehensive loss (1 ) (18 ) 142 (10 ) 113 Net other comprehensive income (loss) $ 67 $ (97 ) $ 135 $ (75 ) $ 30 Balance at March 31, 2019 $ 16 $ (3,882 ) $ (8,341 ) $ (157 ) $ (12,364 ) 2020 Balance at January 1, 2020 $ — $ (1,070 ) $ (345 ) $ (1 ) $ (1,416 ) Other comprehensive loss before reclassifications — (396 ) (2 ) — (398 ) Amounts reclassified from accumulated other comprehensive loss — — 4 — 4 Net other comprehensive (loss) income $ — $ (396 ) $ 2 $ — $ (394 ) Balance at March 31, 2020 $ — $ (1,466 ) $ (343 ) $ (1 ) $ (1,810 ) The tax effects on the net activity related to each component of other comprehensive income (loss) for the three months ended March 31, 2020 and 2019 were as follows: Tax Benefit (Expense) Three Months Ended March 31, In millions 2020 2019 Unrealized gains (losses) on investments $ — $ (18 ) Cumulative translation adjustments — (1 ) Pension and other post employment benefit plans (1 ) (32 ) Derivative instruments — 24 Tax expense from income taxes related to other comprehensive income items $ (1 ) $ (27 )
Schedule of Reclassifications Out of Accumulated Other Comprehensive Income	A summary of the reclassifications out of AOCL for the three months ended March 31, 2020 and 2019 is provided as follows: Reclassifications Out of Accumulated Other Comprehensive Loss Three Months Ended Income Classification In millions 2020 2019 Unrealized gains on investments $ — $ (1 ) See (1) below Tax expense (benefit) — — See (2) below After tax $ — $ (1 ) Cumulative translation adjustments $ — $ (18 ) See (3) below Pension and other post employment benefit plans $ 3 $ 167 See (4) below Tax expense (benefit) 1 (25 ) See (2) below After tax $ 4 $ 142 Derivative Instruments $ — $ (11 ) See (5) below Tax expense — 1 See (2) below After tax $ — $ (10 ) Total reclassifications for the period, after tax $ 4 $ 113 1. "Net sales" and "Sundry income (expense) - net." 2. "Provision for income taxes on continuing operations." 3. "Sundry income (expense) - net." 4. These AOCL components are included in the computation of net periodic benefit cost of the Company's defined benefit pension and other post employment benefit plans. See Note 17 for additional information. 5. "Cost of sales," "Sundry income (expense) - net" and "Interest expense."

NONCONTROLLING INTERESTS (Table

NONCONTROLLING INTERESTS (Tables)	3 Months Ended
	Mar. 31, 2020
Noncontrolling Interest [Abstract]
Schedule Of Noncontrolling Interest	The following table summarizes the activity for equity attributable to noncontrolling interests for the three months ended March 31, 2020 and 2019 : Noncontrolling Interests Three Months Ended March 31, In millions 2020 2019 Balance at beginning of period $ 569 $ 1,608 Net income attributable to noncontrolling interests 6 51 Distributions to noncontrolling interests (6 ) (11 ) Cumulative translation adjustments (8 ) 7 Other 5 (1 ) Balance at end of period $ 566 $ 1,654

PENSION PLANS AND OTHER POSTR_2

PENSION PLANS AND OTHER POSTRETIREMENT BENEFITS (Tables)	3 Months Ended
	Mar. 31, 2020
Retirement Benefits [Abstract]
Schedule of net periodic benefit costs	Net Periodic Benefit (Credit) Cost for All Plans Three Months Ended March 31, In millions 2020 2019 Defined Benefit Pension Plans: Service cost 1 $ 18 $ 131 Interest cost 2 14 447 Expected return on plan assets 3 (28 ) (713 ) Amortization of prior service credit 4 (1 ) (6 ) Amortization of net loss 5 4 133 Net periodic benefit (credit) cost - total $ 7 $ (8 ) Less: Net periodic benefit (credit) cost - discontinued operations — (4 ) Net periodic benefit credit - continuing operations $ 7 $ (4 ) Other Post Employment Benefits: Service cost 1 $ — $ 4 Interest cost 2 — 37 Amortization of net gain 5 — (6 ) Net periodic benefit cost - total $ — $ 35 Less: Net periodic benefit (credit) cost - discontinued operations — 34 Net periodic benefit cost - continuing operations $ — $ 1 1. The service cost from continuing operations was $16 million for the three months ended March 31, 2019. The activity from OPEBs was immaterial. 2. The interest cost from continuing operations was $21 million for the three months ended March 31, 2019. The activity from OPEBs was immaterial. 3. The expected return on plan assets from continuing operations was $43 million for the three months ended March 31, 2019. The activity from OPEBs was immaterial. 4. The amortization of prior service credit from continuing operations was immaterial for the three months ended March 31, 2019 for both pensions and OPEBs. 5. The amortization of unrecognized net loss from continuing operations was $2 million for the three months ended March 31, 2019. The activity from OPEBs was immaterial.

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	3 Months Ended
	Mar. 31, 2020
Investments, All Other Investments [Abstract]
Schedule of the fair value of financial instruments	The following table summarizes the fair value of financial instruments at March 31, 2020 and December 31, 2019 : Fair Value of Financial Instruments March 31, 2020 December 31, 2019 In millions Cost Gain Loss Fair Value Cost Gain Loss Fair Value Cash equivalents $ 771 $ — $ — $ 771 $ 417 $ — $ — $ 417 Restricted cash equivalents 1 $ 34 $ — $ — $ 34 $ 37 $ — $ — $ 37 Total cash and restricted cash equivalents $ 805 $ — $ — $ 805 $ 454 $ — $ — $ 454 Long-term debt including debt due within one year $ (15,620 ) $ 38 $ (1,209 ) $ (16,791 ) $ (15,618 ) $ — $ (1,633 ) $ (17,251 ) Derivatives relating to: Foreign currency 2 — 12 (11 ) 1 — 6 (7 ) (1 ) Total derivatives $ — $ 12 $ (11 ) $ 1 $ — $ 6 $ (7 ) $ (1 ) 1. Classified as "Other current assets" in the interim Condensed Consolidated Balance Sheets. 2. Presented net of cash collateral where master netting arrangements allow.
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	Notional Amounts March 31, 2020 Dec 31, 2019 In millions Derivatives not designated as hedging instruments: Foreign currency contracts 1 $ (344 ) $ 26 Commodity contracts $ 12 $ 11 1. Presented net of contracts bought and sold.
Schedule of fair value of derivative instruments using Level 2 inputs	March 31, 2020 In millions Balance Sheet Classification Gross Counterparty and Cash Collateral Netting 1 Net Amounts Included in the Consolidated Balance Sheet Asset derivatives: Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets $ 34 $ (22 ) $ 12 Total asset derivatives $ 34 $ (22 ) $ 12 Liability derivatives: Derivatives not designated as hedging instruments: Foreign currency contracts Accrued and other current liabilities $ 33 $ (22 ) $ 11 Total liability derivatives $ 33 $ (22 ) $ 11 December 31, 2019 In millions Balance Sheet Classification Gross Counterparty and Cash Collateral Netting 1 Net Amounts Included in the Consolidated Balance Sheet Asset derivatives: Derivatives not designated as hedging instruments: Foreign currency contracts Other current assets $ 16 $ (10 ) $ 6 Total asset derivatives $ 16 $ (10 ) $ 6 Liability derivatives: Derivatives not designated as hedging instruments: Foreign currency contracts Accrued and other current liabilities $ 17 $ (10 ) $ 7 Total liability derivatives $ 17 $ (10 ) $ 7 1. Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the Company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of the fair value of assets and liabilities measured on a recurring basis	The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis: Basis of Fair Value Measurements on a Recurring Basis at March 31, 2020 Significant Other Observable Inputs (Level 2) In millions Assets at fair value: Cash equivalents and restricted cash equivalents 1 $ 805 Derivatives relating to: 2 Foreign currency contracts 34 Total assets at fair value $ 839 Liabilities at fair value: Long-term debt including debt due within one year 3 $ 16,791 Derivatives relating to: 2 Foreign currency contracts 33 Total liabilities at fair value $ 16,824 1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value. 2. See Note 19 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets. 3. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms. Basis of Fair Value Measurements on a Recurring Basis at December 31, 2019 Significant Other Observable Inputs (Level 2) In millions Assets at fair value: Cash equivalents and restricted cash equivalents 1 $ 454 Derivatives relating to: 2 Foreign currency contracts 16 Total assets at fair value $ 470 Liabilities at fair value: Long-term debt including debt due within one year 3 $ 17,251 Derivatives relating to: 2 Foreign currency contracts 17 Total liabilities at fair value $ 17,268 1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value. 2. See Note 19 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets 3. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.

SEGMENTS AND GEOGRAPHIC REGIO_2

SEGMENTS AND GEOGRAPHIC REGIONS (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting Information [Line Items]
Schedule of Operating Segment Information	Segment Information Elect. & Imaging Nutrition & Biosciences Transp. & Industrial Safety & Const. Non-Core Corp. Total In millions Three Months Ended March 31, 2020 Net sales $ 884 $ 1,551 $ 1,144 $ 1,276 $ 366 $ — $ 5,221 Operating EBITDA 1 $ 253 $ 385 $ 308 $ 368 $ 42 $ (35 ) $ 1,321 Equity in earnings of nonconsolidated affiliates $ 9 $ — $ 1 $ 7 $ 22 $ — $ 39 Three months ended March 31, 2019 Net sales $ 825 $ 1,535 $ 1,317 $ 1,283 $ 454 $ — $ 5,414 Pro forma operating EBITDA 1 $ 288 $ 349 $ 373 $ 374 $ 98 $ (52 ) $ 1,430 Equity in earnings of nonconsolidated affiliates 2 $ 3 $ — $ — $ 8 $ 30 $ — $ 41
Reconciliation of Income from Continuing Operations, net of tax to Pro Forma Operating EBITDA	Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Three Months Ended March 31, 2020 and 2019 Three Months Ended March 31, In millions 2020 2019 Loss from continuing operations, net of tax $ (610 ) $ (74 ) + Provision for (benefit from) income taxes on continuing operations 44 (91 ) Loss from continuing operations before income taxes $ (566 ) $ (165 ) + Pro forma adjustments 1 — 122 + Depreciation and amortization 772 527 - Interest income 2 2 40 + Interest expense 3 173 180 - Non-operating pension/OPEB benefit 2 11 21 - Foreign exchange gains (losses), net 2 (8 ) (61 ) + Costs historically allocated to the materials science and agriculture businesses 4 — 256 - Significant items 5 (947 ) (510 ) Operating EBITDA 1 $ 1,321 $ 1,430 1. For the three months ended March 31, 2019 , operating EBITDA is on a pro forma basis. The pro forma adjustment reflects the net pro forma impact of items directly attributable to the Transactions, as applicable. 2. Included in "Sundry income (expense) - net." 3. The three months ended March 31, 2020 excludes N&B financing fee amortization. Refer to details of significant items below. 4. Costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205. 5. The significant items for the three months ended March 31, 2020, are presented on an as reported basis. The adjusted significant items for the three months ended March 31, 2019 are presented on a pro forma basis.
Schedule of Certain Items by Segment	The following tables summarize the pre-tax impact of significant items by segment that are excluded from Operating EBITDA and pro forma Operating EBITDA above: Significant Items by Segment for the Three Months Ended March 31, 2020 Elect. & Imaging Nutrition & Biosciences Transp. & Industrial Safety & Construction Non-Core Corporate Total In millions Integration and separation costs 1 $ — $ — $ — $ — $ — $ (197 ) $ (197 ) Restructuring and asset related charges - net 2 (4 ) (6 ) (25 ) (25 ) — (74 ) (134 ) Goodwill impairment charge 3 — — — — (533 ) — (533 ) Asset impairment charges 4 — — — — (270 ) — (270 ) Gain on divestiture 5 197 — — — — — 197 N&B financing fee amortization 6 — — — — — (10 ) (10 ) Total $ 193 $ (6 ) $ (25 ) $ (25 ) $ (803 ) $ (281 ) $ (947 ) 1. Integration and separation costs related to the post-Merger integration and the intended separation of the N&B Business. 2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information. 3. See Note 11 for additional information. 4. See Note 5 for additional information. 5. Reflected in "Sundry income (expense) - net." Refer to Note 3 for additional information. 6. Reflected in "Interest expense" and relates to the intended separation of the N&B Business. Adjusted Significant Items by Segment for the Three Months Ended March 31, 2019 (Pro Forma) Elect. & Imaging Nutrition & Biosciences Transp. & Industrial Safety & Construction Non-Core Corporate Total In millions Integration and separation costs 1 — — — — — $ (438 ) $ (438 ) Restructuring and asset related charges - net 2 — (27 ) — (2 ) 1 (44 ) (72 ) Total $ — $ (27 ) $ — $ (2 ) $ 1 $ (482 ) $ (510 ) 1. Integration and separation costs related to the Merger, post-Merger integration and business separation activities. 2. Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.

RECENT ACCOUNTING GUIDANCE CECL

RECENT ACCOUNTING GUIDANCE CECL (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained Earnings (Accumulated Deficit)	$ 9,251	$ 8,400

DIVESTITURES Material Sciences

DIVESTITURES Material Sciences Components of Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax	$ 0	$ 646
Income (Loss) from Discontinued Operations, Attributable to Noncontrolling Interests, Net of Tax	$ 0	(47)
Materials Science Division [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net Sales, Discontinued Operation		10,867
Cost of Sales, Discontinued Operations		8,917
Research and Development Expense, Discontinued Operations		163
Selling, General and Administrative Expense, Discontinued Operations		329
Amortization of Intangibles, Discontinued Operations		116
Restructuring and Asset Related Charges - Net, Discontinued Operations		157
Integration and Separation Costs, Discontinued Operations		44
Equity in Earnings on Nonconsolidated Affiliates, Discontinued Operations		(13)
Sundry Income (expense), Discontinued Operations		99
Interest Expense, Discontinued Operations		240
Income (Loss) from Discontinued Operation, before Income Tax		987
Provision for Income Taxes on Discontinued Operations		261
Income from discontinued operations, net of tax		726
Income (Loss) from Discontinued Operations, Attributable to Noncontrolling Interests, Net of Tax		37
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent		$ 689

DIVESTITURES Materials Science

DIVESTITURES Materials Science Components of Cash Flows & Other (Details) - USD ($) $ in Millions	Apr. 01, 2019	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contributions to Dow	$ 2,024
Materials Science Division [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Depreciation and Amortization		$ 744
Capital Expenditure, Discontinued Operations		$ 597

DIVESTITURES Agriculture Divisi

DIVESTITURES Agriculture Division Components of Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax	$ 0	$ 646
Income (Loss) from Discontinued Operations, Attributable to Noncontrolling Interests, Net of Tax	$ 0	(47)
Agriculture Division [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net Sales, Discontinued Operation		3,368
Cost of Sales, Discontinued Operations		2,192
Research and Development Expense, Discontinued Operations		287
Selling, General and Administrative Expense, Discontinued Operations		617
Amortization of Intangibles, Discontinued Operations		102
Restructuring and Asset Related Charges - Net, Discontinued Operations		59
Integration and Separation Costs, Discontinued Operations		158
Equity in Earnings on Nonconsolidated Affiliates, Discontinued Operations		(1)
Sundry Income (expense), Discontinued Operations		65
Interest Expense, Discontinued Operations		63
Income (Loss) from Discontinued Operation, before Income Tax		(46)
Provision for Income Taxes on Discontinued Operations		34
Income from discontinued operations, net of tax		(80)
Income (Loss) from Discontinued Operations, Attributable to Noncontrolling Interests, Net of Tax		10
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent		$ (90)

DIVESTITURES Agriculture Divi_2

DIVESTITURES Agriculture Division Components of Cash Flows & Other (Details) - USD ($) $ in Millions	Jun. 01, 2019	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contribution to Corteva	$ 7,139
Agriculture Division [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Depreciation and Amortization		$ 249
Capital Expenditure, Discontinued Operations		$ 222

DIVESTITURES Indemnifications (

DIVESTITURES Indemnifications (Details) $ in Millions	Mar. 31, 2020USD ($)
Accounts And Notes Receivable, Other
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Indemnification Asset	$ 134
Deferred Charges And Other Assets [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Indemnification Asset	141
Accrued and other current liabilities
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Indemnification Liabilities	80
Other noncurrent obligations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Indemnification Liabilities	$ 95

DIVESTITURES Other Divestitures

DIVESTITURES Other Divestitures (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Integration and separation costs		$ 197	$ 611
Gain (Loss) on Disposition of Business	[1]	197
Electronics & Imaging
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses		420
Gain (Loss) on Disposition of Business	[1]	197
Gain (Loss) on Disposition of Business, Net of Tax		$ 102
[1]	Reflected in "Sundry income (expense) - net." Refer to Note 3 for additional information.

REVENUE (Details)

REVENUE (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2020		Mar. 31, 2019	Dec. 31, 2019
Net sales		$ 5,221		$ 5,414
Revenue recognized which was deferred at the beginning of the period		14		10
Accounts and notes receivable - Trade	[1]	3,156			$ 3,007
Contract assets - current	[2]	32			35
Deferred revenue - current	[3]	69			43
Deferred revenue - noncurrent	[4]	29			$ 34
Image Solutions
Net sales		148		154
Interconnect Solutions
Net sales		266		238
Semiconductor Technologies
Net sales		470		433
Food & Beverage
Net sales		738		755
Health & Biosciences
Net sales		605		570
Pharma Solutions
Net sales		208		210
Healthcare & Specialty
Net sales		359		384
Industrial & Consumer
Net sales		266		308
Mobility Solutions
Net sales		519		625
Safety Solutions
Net sales		631		665
Shelter Solutions
Net sales		348		357
Water Solutions
Net sales		297		261
Biomaterials
Net sales		34		59
Clean Technologies
Net sales		60		65
DuPont Teijin Films
Net sales		43		37
Photovoltaic & Advanced Materials
Net sales		229		254
Sustainable Solutions
Net sales		0	[5]	39
Electronics & Imaging
Net sales		884		825
Nutrition & Biosciences
Net sales		1,551		1,535
Transportation & Industrial
Net sales		1,144		1,317
Safety & Construction
Net sales		1,276		1,283
Non-core
Net sales		366		454
U.S. & Canada
Net sales		1,742		1,776
EMEA
Net sales	[6]	1,271		1,380
Asia Pacific
Net sales		1,913		1,945
Latin America
Net sales		$ 295		$ 313
[1]	Included in "Accounts and notes receivable - net" in the interim Condensed Consolidated Balance Sheets.
[2]	Included in "Other current assets" in the interim Condensed Consolidated Balance Sheets.
[3]	Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets.
[4]	Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheets.
[5]	The Sustainable Solutions business was divested in the third quarter of 2019.
[6]	Europe, Middle East and Africa.

RESTRUCTURING AND ASSET RELAT_3

RESTRUCTURING AND ASSET RELATED CHARGES - NET (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges		$ 404	$ 71
Restructuring Reserve		230		$ 162
Asset Impairment Charges	[1]	270
Non-core [Member]
Restructuring Cost and Reserve [Line Items]
Asset Impairment Charges	[1]	$ 270
[1]	See Note 5 for additional information.

RESTRUCTURING AND ASSET RELAT_4

RESTRUCTURING AND ASSET RELATED CHARGES - NET 2020 Restructuring Program (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 230	$ 162
2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	111
Employee Severance [Member] | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	96
Asset Related Charges And Other [Member] | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	15
Electronics & Imaging | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	4
Nutrition & Biosciences | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	6
Transportation & Industrial | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	24
Safety & Construction | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	20
Non-core [Member] | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	0
Corporate | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	57
Accrued and other current liabilities | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	96
Maximum | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	180
Maximum | Employee Severance [Member] | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	125
Maximum | Asset Related Charges And Other [Member] | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	50
Maximum | Contract Termination [Member] | 2020 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	$ 5

RESTRUCTURING AND ASSET RELAT_5

RESTRUCTURING AND ASSET RELATED CHARGES - NET 2019 Restructuring Program (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 230	$ 230	$ 162
2019 Restructuring Program [Domain]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		156
2019 Restructuring Program [Domain] | Accrued and other current liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	75	75	86
2019 Restructuring Program [Domain] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	18	122
Non-cash compensation	(6)
Cash Payments	(23)
Restructuring Reserve	75	75	$ 86
2019 Restructuring Program [Domain] | Asset Related Charges And Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		$ 34
2019 Restructuring Program [Domain] | Transportation & Industrial
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	1
2019 Restructuring Program [Domain] | Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 17

RESTRUCTURING AND ASSET RELAT_6

RESTRUCTURING AND ASSET RELATED CHARGES - NET DowDuPont Cost Synergy Program (Details) - USD ($) $ in Millions	3 Months Ended				31 Months Ended
	Mar. 31, 2020		Mar. 31, 2019		Mar. 31, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges	$ 404		$ 71
Restructuring Reserve	230				$ 230	$ 162
Non-core [Member] | Income (Loss) From Equity Method Investments [Domain]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			1
DowDuPont Cost Synergy Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges					490
Restructuring Reserve	59				59	76
Restructuring Charges	5	[1]	72	[2]
Cash Payments	(22)
DowDuPont Cost Synergy Program [Member] | Restructuring Settlement And Impairment Provisions [Domain]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	5		71
DowDuPont Cost Synergy Program [Member] | Income (Loss) From Equity Method Investments [Domain]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			1
DowDuPont Cost Synergy Program [Member] | Accrued and other current liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	59				59	76
DowDuPont Cost Synergy Program [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges					215
Restructuring Reserve	52				52	74
Restructuring Charges	0		43
Cash Payments	(22)
DowDuPont Cost Synergy Program [Member] | Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges					66
Restructuring Reserve	7				7	$ 2
Restructuring Charges	5		16
Cash Payments	0
DowDuPont Cost Synergy Program [Member] | Asset Related Charges And Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges					$ 209
Restructuring Charges	0		13
DowDuPont Cost Synergy Program [Member] | Nutrition & Biosciences
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			27
DowDuPont Cost Synergy Program [Member] | Safety & Construction
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 5		2
DowDuPont Cost Synergy Program [Member] | Non-core [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			(1)
DowDuPont Cost Synergy Program [Member] | Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			$ 44
[1]	The charges for the three months ended March 31, 2020 include $5 million
[2]	The charges for the three months ended March 31, 2019 include $27 million related to Nutrition & Biosciences, $2 million related to Safety and Construction, $44 million related to Corporate, and a benefit of $1 million related to Non Core.

SUPPLEMENTARY INFORMATION - Sum

SUPPLEMENTARY INFORMATION - Summary of Sundry Income (Expense) - Net (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2020		Mar. 31, 2019
Schedule Of Sundry Income (Expense) [Line Items]
Non-operating pension and other post employment benefit (OPEB) credits		$ 11	[1]	$ 21
Interest income		2	[1]	40
Net gain on divestiture and sales of other assets and investments		197	[2]	53	[3]
Gain (Loss) on Disposition of Business	[4]	197
Foreign exchange gains (losses), net		(8)	[1]	(61)
Miscellaneous Income (Expense), Net		9		31	[5]
Sundry income (expense) - net		211		84
Electronics & Imaging
Schedule Of Sundry Income (Expense) [Line Items]
Net gain on divestiture and sales of other assets and investments		51
Gain (Loss) on Disposition of Business	[4]	$ 197
Safety & Construction
Schedule Of Sundry Income (Expense) [Line Items]
Proceeds from License Fees Received				$ 26
[1]	Included in "Sundry income (expense) - net."
[2]	The three months ended March 31, 2020 reflects income of $197 million
[3]	The three months ended March 31, 2019 includes income of $51 million
[4]	Reflected in "Sundry income (expense) - net." Refer to Note 3 for additional information.
[5]	Miscellaneous income (expenses) - net for the three months ended March 31, 2019 includes $26 million related to licensing income within the Safety & Construction segment.

SUPPLEMENTARY INFORMATION - Cas

SUPPLEMENTARY INFORMATION - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Supplementary Information
Restricted cash and cash equivalents	$ 34	$ 37
Accrued and other current liabilities	$ 1,434	1,342
Employee-related Liabilities		$ 479

INCOME TAXES Effective Income T

INCOME TAXES Effective Income Tax Rate (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Contingency [Line Items]
Effective Income Tax Rate Reconciliation, Percent	(7.80%)	55.20%

EARNINGS PER SHARE CALCULATIO_3

EARNINGS PER SHARE CALCULATIONS - Summary of Net Income for EPS Calculations, Basic (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Loss from continuing operations, net of tax		$ (610)	$ (74)
Net income from continuing operations attributable to noncontrolling interests		6	4
Net income from continuing operations attributable to participating securities	[1]	0	1
Loss from continuing operations attributable to common stockholders		(616)	(79)
Income from discontinued operations, net of tax		0	646
Net income from discontinued operations attributable to noncontrolling interests		0	47
Income from discontinued operations attributable to common stockholders		0	599
Net (loss) income attributable to common stockholders		$ (616)	$ 520
[1]	Historical Dow restricted stock units are considered participating securities due to Historical Dow's practice of paying dividend equivalents on unvested shares.

EARNINGS PER SHARE CALCULATIO_4

EARNINGS PER SHARE CALCULATIONS - Summary of EPS Calculations, Basic (Details) - $ / shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Loss from continuing operations attributable to common stockholders	$ (0.83)	$ (0.11)
Income from discontinued operations, net of tax	0	0.80
Net (loss) income attributable to common stockholders	$ (0.83)	$ 0.69

EARNINGS PER SHARE CALCULATIO_5

EARNINGS PER SHARE CALCULATIONS - Summary of EPS Calculations, Diluted (Details) - $ / shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Loss from continuing operations attributable to common stockholders	$ (0.83)	$ (0.11)
Income from discontinued operations, net of tax	0	0.80
Net (loss) income attributable to common stockholders	$ (0.83)	$ 0.69

EARNINGS PER SHARE CALCULATIO_6

EARNINGS PER SHARE CALCULATIONS - Summary of Count Information (Details) - $ / shares shares in Millions		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019	May 01, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Par Value		$ 0.01		$ 0.01	$ 0.01
Weighted-average common shares - basic		738.6	750
Plus dilutive effect of equity compensation plans		0	0
Weighted-average common shares - diluted		738.6	750
Stock options and restricted stock units excluded from EPS calculations	[1]	6.4	6.4
[1]	These outstanding options to purchase shares of common stock and restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive.

INVENTORIES (Summary of Invento

INVENTORIES (Summary of Inventory) (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Finished goods	$ 2,731	$ 2,621
Work in process	858	855
Raw materials	589	599
Supplies	232	244
Total inventories	$ 4,410	$ 4,319

NONCONSOLIDATED AFFILIATES NONC

NONCONSOLIDATED AFFILIATES NONCONSOLIDATED AFFILIATES - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)entity	Mar. 31, 2019	Dec. 31, 2019USD ($)
Investments in and Advances to Affiliates [Line Items]
Investments in nonconsolidated affiliates	$ 1,227		$ 1,204
Accrued and other current liabilities	(84)		(85)
Other noncurrent obligations	(351)		(358)
Net of investment in nonconsolidated affiliates	$ 792		$ 761
Equity Method Investment Ownership Interest Number Of Affiliates | entity	21
Equity Method Investee [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Investments in and Advances to Affiliates [Line Items]
Concentration Risk, Percentage	3.00%	3.00%
Equity Method Investee [Member] | Supplier Concentration Risk [Member] | Cost of Goods and Service Benchmark [Member]
Investments in and Advances to Affiliates [Line Items]
Concentration Risk, Percentage	2.00%	2.00%

NONCONSOLIDATED AFFILIATES NO_2

NONCONSOLIDATED AFFILIATES NONCONSOLIDATED AFFILIATES - Principal Nonconsolidated Affiliates (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]
Investments in nonconsolidated affiliates		$ 1,227		$ 1,204
Other noncurrent obligations		$ (351)		(358)
DC HSC Holdings LLC [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage	[1]	50.00%
Investments in nonconsolidated affiliates		$ 97		87
Principal nonconsolidated affiliate [Member]
Schedule of Equity Method Investments [Line Items]
Summarized Financial Information, Revenue	[2]	185	$ 185
Summarized Financial Information, Cost of Sales	[2]	127	107
Summarized Financial Information, Income from Continuing Operations		40	63
Summarized Financial Information, Net Income attributed to entities		35	52
Summarized Financial Information, Intercompany Revenue and Cost of Sales		$ 22	$ 21
Hemlock Semiconductor L.L.C. [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage		50.10%
Other noncurrent obligations		$ (351)		$ (358)
DC HSC Holdings LLC [Member] | Hemlock Semiconductor L.L.C. [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage		80.50%
[1]	DC HSC Holdings LLC holds an 80.5 percent indirect ownership interest in Hemlock Semiconductor Operations LLC.
[2]	Includes sales and cost of sales of $22 million and $21 million for the three months ended March 31, 2020 and 2019, respectively, that have not been eliminated between Hemlock Semiconductor L.L.C and DC HSC Holdings in the presentation of the summarized income statement information above.

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2020		Mar. 31, 2019
Goodwill [Line Items]
Goodwill impairment charge		$ 533	[1]	$ 0
Non-core [Member]
Goodwill [Line Items]
Goodwill impairment charge	[1]	$ 533
[1]	See Note 11 for additional information.

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Goodwill (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2020		Mar. 31, 2019
Goodwill [Roll Forward]
Net goodwill, beginning of period		$ 33,151
Goodwill, Acquisitions		53
Goodwill, Divestitures		(199)
Goodwill impairment charge		(533)	[1]	$ 0
Currency Translation Adjustment		(173)
Goodwill, Measurement Period Adjustments		18
Net goodwill, end of period		32,317
Electronics & Imaging
Goodwill [Roll Forward]
Net goodwill, beginning of period		7,092
Goodwill, Acquisitions		0
Goodwill, Divestitures		(199)
Goodwill impairment charge		0
Currency Translation Adjustment		(11)
Goodwill, Measurement Period Adjustments		0
Net goodwill, end of period		6,882
Nutrition & Biosciences
Goodwill [Roll Forward]
Net goodwill, beginning of period		11,012
Goodwill, Acquisitions		0
Goodwill, Divestitures		0
Goodwill impairment charge		0
Currency Translation Adjustment		(111)
Goodwill, Measurement Period Adjustments		0
Net goodwill, end of period		10,901
Transportation & Industrial
Goodwill [Roll Forward]
Net goodwill, beginning of period		6,931
Goodwill, Acquisitions		0
Goodwill, Divestitures		0
Goodwill impairment charge		0
Currency Translation Adjustment		(25)
Goodwill, Measurement Period Adjustments		0
Net goodwill, end of period		6,906
Safety & Construction
Goodwill [Roll Forward]
Net goodwill, beginning of period		6,711
Goodwill, Acquisitions		53
Goodwill, Divestitures		0
Goodwill impairment charge		0
Currency Translation Adjustment		(26)
Goodwill, Measurement Period Adjustments		18
Net goodwill, end of period		6,756
Non-core [Member]
Goodwill [Roll Forward]
Net goodwill, beginning of period		1,405
Goodwill, Acquisitions		0
Goodwill, Divestitures		0
Goodwill impairment charge	[1]	(533)
Currency Translation Adjustment		0
Goodwill, Measurement Period Adjustments		0
Net goodwill, end of period		$ 872
[1]	See Note 11 for additional information.

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Other Intangible Assets (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Finite other intangible assets, gross carrying amount	$ 15,992	$ 16,065
Finite other intangible assets, accumulated amortization	(4,831)	(4,143)
Finite other intangible assets, net	11,161	11,922
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	1,673	1,671
Intangible Assets, Gross (Excluding Goodwill)	17,665	17,736
Other intangible assets, net	12,834	13,593
Trademarks / tradenames
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	1,673	1,671
Developed technology
Finite-Lived Intangible Assets [Line Items]
Finite other intangible assets, gross carrying amount	4,356	4,343
Finite other intangible assets, accumulated amortization	(1,523)	(1,361)
Finite other intangible assets, net	2,833	2,982
Trademarks / tradenames
Finite-Lived Intangible Assets [Line Items]
Finite other intangible assets, gross carrying amount	2,416	2,433
Finite other intangible assets, accumulated amortization	(755)	(455)
Finite other intangible assets, net	1,661	1,978
Customer-related
Finite-Lived Intangible Assets [Line Items]
Finite other intangible assets, gross carrying amount	8,920	8,986
Finite other intangible assets, accumulated amortization	(2,339)	(2,229)
Finite other intangible assets, net	6,581	6,757
Other Intangible Assets
Finite-Lived Intangible Assets [Line Items]
Finite other intangible assets, gross carrying amount	300	303
Finite other intangible assets, accumulated amortization	(214)	(98)
Finite other intangible assets, net	$ 86	$ 205

GOODWILL AND OTHER INTANGIBLE_6

GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Amortization of intangibles	$ 533	$ 256
Remainder of 2020	1,595
2021	1,008
2022	968
2023	925
2024	826
2025	$ 789

GOODWILL AND OTHER INTANGIBLE_7

GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Intangibles by Segment (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Schedule of Intangible Assets [Line Items]
Other intangible assets	$ 12,834	$ 13,593
Electronics & Imaging
Schedule of Intangible Assets [Line Items]
Other intangible assets	1,764	1,833
Nutrition & Biosciences
Schedule of Intangible Assets [Line Items]
Other intangible assets	3,989	4,377
Transportation & Industrial
Schedule of Intangible Assets [Line Items]
Other intangible assets	3,524	3,590
Safety & Construction
Schedule of Intangible Assets [Line Items]
Other intangible assets	3,048	3,082
Non-core [Member]
Schedule of Intangible Assets [Line Items]
Other intangible assets	$ 509	$ 711

SHORT TERM BORROWINGS, LONG-T_2

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES Narrative (Details) - USD ($) $ in Millions	Apr. 09, 2020	Mar. 31, 2020	May 01, 2020	Apr. 16, 2020
Senior floating rate note due 2020 [Member]
Debt Instrument [Line Items]
Senior Notes, Current		$ 500
Senior Fixed Rate Notes due 2020 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		3.77%
Senior Notes, Current		$ 1,500
Old 364-day Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		750
Proceeds from Lines of Credit		$ 250
Subsequent Event [Member] | Old 364-day Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Repayments of Lines of Credit	$ 250
Subsequent Event [Member] | 1B Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				$ 1,000
Unsecured Debt [Member] | Subsequent Event [Member] | Senior unsecured notes due 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 2,000
Debt Instrument, Interest Rate, Stated Percentage			2.169%

SHORT TERM BORROWINGS, LONG-T_3

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES Nutrition & Biosciences Financing (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Line of Credit Facility [Line Items]
one-time cash payment related to proposed N&B transaction	$ 7,300
N&B senior unsecured term loan facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	1,250
N&B Bridge Loan [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 6,250	$ 7,500

COMMITMENTS AND CONTINGENT LI_3

COMMITMENTS AND CONTINGENT LIABILITIES - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Loss Contingencies [Line Items]
Estimated Litigation Liability	$ 24
Accrual for Environmental Loss Contingencies	77	$ 77
Accrual For Environmental Loss Contingencies, Potential Exposure In Excess Of Accrual	171
Non-PFAS Stray Liabilities Threshold	200
Indemnifiable Losses Threshold related to PFAS Stray Liabilities - Total	300
Indemnifiable Losses Threshold related to PFAS Stray Liabilities - Per Party	150
Retained and Assumed at Divestiture [Domain]
Loss Contingencies [Line Items]
Estimated Litigation Liability	3
Accrual for Environmental Loss Contingencies	35
Accrual For Environmental Loss Contingencies, Potential Exposure In Excess Of Accrual	108
Indemnification Agreement [Member] | Litigation and Environmental [Domain]
Loss Contingencies [Line Items]
Indemnification Liabilities	$ 58
DuPont and Corteva
Loss Contingencies [Line Items]
Percentage Split of PFAS Liabilities under the Separation Agreement	50.00%
DuPont
Loss Contingencies [Line Items]
Non-PFAS Stray Liabilities percent split after Threshold	71.00%
DuPont | Indemnification Agreement [Member]
Loss Contingencies [Line Items]
Accrual for Environmental Loss Contingencies	$ 42
DuPont | Corteva | Indemnification Agreement [Member]
Loss Contingencies [Line Items]
Accrual for Environmental Loss Contingencies	34
DuPont | Dow | Indemnification Agreement [Member]
Loss Contingencies [Line Items]
Accrual for Environmental Loss Contingencies	$ 8
Corteva
Loss Contingencies [Line Items]
Non-PFAS Stray Liabilities percent split after Threshold	29.00%

COMMITMENTS AND CONTINGENT LI_4

COMMITMENTS AND CONTINGENT LIABILITIES - PFOA & Natural Resources (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)	Mar. 31, 2017USD ($)	Apr. 30, 2020	Dec. 31, 2004USD ($)
Firefighter Foam Cases [Domain] | DuPont
Loss Contingencies [Line Items]
Number of lawsuits			565
Firefighter Foam Cases [Domain] | Historical EID And Chemours
Loss Contingencies [Line Items]
Number of lawsuits			600
Chemours Suit [Member] | DuPont and Corteva
Loss Contingencies [Line Items]
Claim related to pending litigation	$ 3,910
PFOA Multi-District Litigation (MDL)
Loss Contingencies [Line Items]
Number of lawsuits	80
Abbott Case [Member]
Loss Contingencies [Line Items]
Litigation Settlement, Amount Awarded to Other Party	$ 50
PFOA Multi-District Litigation (MDL) | Chemours
Loss Contingencies [Line Items]
Additional annual PFOA liabilities paid by Chemours	25
PFOA Multi-District Litigation (MDL) | Historical EID
Loss Contingencies [Line Items]
Additional annual PFOA liabilities paid by Historical EID	$ 25
PFOA Matters | PFOA Multi-District Litigation (MDL) | Historical EID
Loss Contingencies [Line Items]
Number of Plaintiffs		3,550
PFOA Matters | PFOA Multi-District Litigation (MDL) | Historical EID And Chemours
Loss Contingencies [Line Items]
Litigation Settlement, Amount Awarded to Other Party		$ 335
PFOA Matters | Leach v. DuPont [Member] | Historical EID
Loss Contingencies [Line Items]
Litigation Settlement, Medical Monitoring Program, Escrow Account, Disbursements				$ 235
Natural Resources and Other Environmental [Member]
Loss Contingencies [Line Items]
Number of lawsuits	100
NORTH CAROLINA | PFOA Matters | Historical EID And Chemours
Loss Contingencies [Line Items]
Number of Plaintiffs	100

COMMITMENTS AND CONTINGENT LI_5

COMMITMENTS AND CONTINGENT LIABILITIES - Environmental Matters (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Site Contingency [Line Items]
Accrual for Environmental Loss Contingencies	$ 77	$ 77
Accrual For Environmental Loss Contingencies, Potential Exposure In Excess Of Accrual	171
Retained and Assumed at Divestiture [Domain]
Site Contingency [Line Items]
Accrual for Environmental Loss Contingencies	35
Accrual For Environmental Loss Contingencies, Potential Exposure In Excess Of Accrual	108
Indemnification Agreement [Member] | DuPont
Site Contingency [Line Items]
Accrual for Environmental Loss Contingencies	42
Indemnification Agreement [Member] | Dow | DuPont
Site Contingency [Line Items]
Accrual for Environmental Loss Contingencies	8
Indemnification Agreement [Member] | Corteva | DuPont
Site Contingency [Line Items]
Accrual for Environmental Loss Contingencies	$ 34

COMMITMENTS AND CONTINGENT LI_6

COMMITMENTS AND CONTINGENT LIABILITIES - Summary of Guarantees (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Guarantor Obligations [Line Items]
Guarantor Obligations, Maximum Exposure, Undiscounted	$ 185	$ 187
Customer and Supplier Guarantee Bank Borrowings [Member]
Guarantor Obligations [Line Items]
Guarantor Obligations, Maximum Exposure, Undiscounted	$ 21
Guarantor Obligations, Liquidation Proceeds, Percentage	10.00%
Equity Affiliates Guarantee Bank Borrowings [Member]
Guarantor Obligations [Line Items]
Guarantor Obligations, Maximum Exposure, Undiscounted	$ 164
Current Portion [Member] | Customer and Supplier Guarantee Bank Borrowings [Member]
Guarantor Obligations [Line Items]
Guarantor Obligations, Maximum Exposure, Undiscounted	$ 21

LEASES (Details)

LEASES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating Lease, Cost	$ 42	$ 44
Operating Lease, Payments	42	$ 41
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 57

LEASES Schedule of Leases (Deta

LEASES Schedule of Leases (Details) - USD ($) $ in Millions		Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating Lease, Right-of-Use Asset	[1]	$ 589	$ 556
Operating Lease, Liability, Current	[2]	143	138
Operating Lease, Liability, Noncurrent	[3]	444	416
Operating Lease, Liability		$ 587	$ 554
[1]	Included in "Deferred charges and other assets" in the interim Condensed Consolidated Balance Sheet.
[2]	Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheet.
[3]	Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheet.

STOCKHOLDERS' EQUITY - Summary

STOCKHOLDERS' EQUITY - Summary of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax			$ (1,810)	$ (1,416)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 40,117	$ 93,820	40,117	41,556	$ 95,900
Other comprehensive loss before reclassifications	(398)	(83)
Amounts reclassified from accumulated other comprehensive loss	4	113
Net other comprehensive income (loss)	(394)	30
Total other comprehensive (loss) income	(402)	36
Ending balance	40,117	93,820
Tax expense from income taxes related to other comprehensive income items	(1)	(27)
Unrealized Gains (Losses) on Investments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	0	16	0	0	(51)
Other comprehensive loss before reclassifications	0	68
Amounts reclassified from accumulated other comprehensive loss	0	(1)
Net other comprehensive income (loss)	0	67
Ending balance	0	16
Tax expense from income taxes related to other comprehensive income items	0	(18)
Cumulative translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(1,466)	(3,882)	(1,466)	(1,070)	(3,785)
Other comprehensive loss before reclassifications	(396)	(79)
Amounts reclassified from accumulated other comprehensive loss	0	(18)
Net other comprehensive income (loss)	(396)	(97)
Ending balance	(1,466)	(3,882)
Tax expense from income taxes related to other comprehensive income items	0	(1)
Pension and other post employment benefit plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(343)	(8,341)	(343)	(345)	(8,476)
Other comprehensive loss before reclassifications	(2)	(7)
Amounts reclassified from accumulated other comprehensive loss	4	142
Net other comprehensive income (loss)	2	135
Ending balance	(343)	(8,341)
Tax expense from income taxes related to other comprehensive income items	(1)	(32)
Derivative Instruments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(1)	(157)	(1)	(1)	(82)
Other comprehensive loss before reclassifications	0	(65)
Amounts reclassified from accumulated other comprehensive loss	0	(10)
Net other comprehensive income (loss)	0	(75)
Ending balance	(1)	(157)
Tax expense from income taxes related to other comprehensive income items	0	24
Total
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(1,810)	(12,364)	$ (1,810)	$ (1,416)	$ (12,394)
Total other comprehensive (loss) income	(394)	30
Ending balance	$ (1,810)	$ (12,364)

STOCKHOLDERS' EQUITY - Summar_2

STOCKHOLDERS' EQUITY - Summary of Reclassifications Out of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period (net of tax)		$ 4	$ 113
Cumulative Translation Adjustment		211	84
Unrealized gains on investments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period (net of tax)		0	(1)
Cumulative translation adjustments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period (net of tax)		0	(18)
Pension and other post employment benefit plans
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period (net of tax)		4	142
Derivative Instruments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period (net of tax)		0	(10)
Reclassification out of Accumulated Other Comprehensive Loss
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period (net of tax)		4	113
Reclassification out of Accumulated Other Comprehensive Loss | Unrealized gains on investments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before tax	[1]	0	(1)
Tax expense (benefit)	[2]	0	0
Total reclassifications for the period (net of tax)		0	(1)
Reclassification out of Accumulated Other Comprehensive Loss | Cumulative translation adjustments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cumulative Translation Adjustment	[3]	0	(18)
Reclassification out of Accumulated Other Comprehensive Loss | Pension and other post employment benefit plans
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before tax	[4]	3	167
Tax expense (benefit)	[2]	1	(25)
Total reclassifications for the period (net of tax)		4	142
Reclassification out of Accumulated Other Comprehensive Loss | Derivative Instruments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before tax	[5]	0	(11)
Tax expense (benefit)	[2]	0	1
Total reclassifications for the period (net of tax)		$ 0	$ (10)
[1]	"Net sales" and "Sundry income (expense) - net."
[2]	"Provision for income taxes on continuing operations."
[3]	"Sundry income (expense) - net."
[4]	These AOCL components are included in the computation of net periodic benefit cost of the Company's defined benefit pension and other post employment benefit plans. See Note 17 for additional information.
[5]	"Cost of sales," "Sundry income (expense) - net" and "Interest expense."

STOCKHOLDERS' EQUITY Stockholde

STOCKHOLDERS' EQUITY Stockholders' Equity Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended	10 Months Ended
	Mar. 31, 2020	Mar. 31, 2020	May 01, 2020	Dec. 31, 2019	Jun. 01, 2019
Equity, Class of Treasury Stock [Line Items]
Retirement of treasury stock	$ 0
Par Value	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Stock Repurchase Program, Authorized Amount					$ 2,000
Stock Repurchased and Retired During Period, Shares	6,100	16,900
Payments for Repurchase of Common Stock	$ 232	$ 982

NONCONTROLLING INTERESTS - Summ

NONCONTROLLING INTERESTS - Summary of Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance at beginning of period	$ 569	$ 1,608
Net income attributable to noncontrolling interests	6	51
Distributions to noncontrolling interests	(6)	(11)
Cumulative translation adjustments	(8)	7
Other	5	(1)
Balance at end of period	$ 566	$ 1,654

PENSION PLANS AND OTHER POSTR_3

PENSION PLANS AND OTHER POSTRETIREMENT BENEFITS (Summary of Net Periodic Benefit Costs) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020		Mar. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Employer Contributions, Remainder of Fiscal Year	$ 60
Net periodic benefit (credit) cost - total	11	[1]	$ 21
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	18		131	[2]
Interest cost	14		447	[3]
Expected return on plan assets	(28)		(713)	[4]
Amortization of prior service credit	(1)		(6)	[5]
Amortization of net (gain) loss	4		133	[6]
Net periodic benefit (credit) cost - total	7		(8)
Other Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	0		4
Interest cost	0		37
Amortization of net (gain) loss	0		(6)
Net periodic benefit (credit) cost - total	0		35
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit (credit) cost - total	0		(4)
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member] | Other Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit (credit) cost - total	0		34
Continuing Operations [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost			16
Interest cost			21
Expected return on plan assets			(43)
Amortization of net (gain) loss			2
Net periodic benefit (credit) cost - total	7		(4)
Continuing Operations [Member] | Other Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit (credit) cost - total	$ 0		$ 1
[1]	Included in "Sundry income (expense) - net."
[2]	The service cost from continuing operations was $16 million for the three months ended March 31, 2019. The activity from OPEBs was immaterial.
[3]	The interest cost from continuing operations was $21 million for the three months ended March 31, 2019. The activity from OPEBs was immaterial.
[4]	The expected return on plan assets from continuing operations was $43 million for the three months ended March 31, 2019. The activity from OPEBs was immaterial.
[5]	The amortization of prior service credit from continuing operations was immaterial for the three months ended March 31, 2019 for both pensions and OPEBs.
[6]	The amortization of unrecognized net loss from continuing operations was $2 million for the three months ended March 31, 2019. The activity from OPEBs was immaterial.

STOCK-BASED COMPENSATION (DuPon

STOCK-BASED COMPENSATION (DuPont) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	10
Share-based Payment Arrangement, Expense	$ 41	$ 21
Share-based Payment Arrangement, Expense, Tax Benefit	$ 9	$ 4
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0.8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 8.84
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 53.50
Restricted Stock Units (RSUs) [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 53.49
Performance Shares [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	0.3
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 50.23

FINANCIAL INSTRUMENTS (Summary

FINANCIAL INSTRUMENTS (Summary of Fair Value of Financial Instruments) (Details) - USD ($) $ in Millions		Mar. 31, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Cash Equivalents, Cost		$ 771	$ 417
Cash Equivalents,Gain		0	0
Cash Equivalents, Loss		0	0
Cash Equivalents, Fair Value		771	417
Restricted Cash, Cost	[1]	34	37
Restricted Cash, Gain	[1]	0	0
Restricted Cash, Loss	[1]	0	0
Restricted Cash, Fair Value	[1]	34	37
Cash and Restricted Cash Equivalents, Marketable Securities and Other Investments, Cost		805	454
Cash and Restricted Cash Equivalents, Marketable Securities and Other Investments, Gain		0	0
Cash and Restricted Cash Equivalents, Marketable Securities and Other Investments, Loss		0	0
Cash and Restricted Cash Equivalents, Marketable Securities and Other Investments, Fair Value		805	454
Long-term debt including debt due within one year, Cost		(15,620)	(15,618)
Long Term Debt including debt due within one year, Gain		38	0
Long Term Debt including debt due within one year, Loss		(1,209)	(1,633)
Long Term Debt, Including Debt Due within one year, Fair Value		(16,791)	(17,251)
Derivative Assets (Liabilities), Gain		12	6
Derivative Assets (Liabilities), Loss		(11)	(7)
Derivative Assets (Liabilities), Fair Value		1	(1)
Foreign Exchange Contract
Debt Securities, Available-for-sale [Line Items]
Derivative Assets (Liabilities), Gain		12	6
Derivative Assets (Liabilities), Loss		(11)	(7)
Derivative Assets (Liabilities), Fair Value		$ 1	$ (1)
[1]	Classified as "Other current assets" in the interim Condensed Consolidated Balance Sheets.

FINANCIAL INSTRUMENTS (Derivati

FINANCIAL INSTRUMENTS (Derivatives) (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Millions		Mar. 31, 2020	Dec. 31, 2019
Derivatives, Fair Value [Line Items]
Derivative Asset, Gross		$ 34	$ 16
Counterparty and Cash Collateral Netting, Assets		(22)	(10)
Net Assets included in Consolidated Balance Sheet		12	6
Derivative Liability, Gross		33	17
Counterparty and Cash Collateral Netting, Liabilities		(22)	(10)
Net Liability included in Consolidated Balance Sheet		11	7
Other Current Assets [Member] | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Derivative Asset, Gross		34	16
Counterparty and Cash Collateral Netting, Assets	[1]	(22)	(10)
Net Assets included in Consolidated Balance Sheet		12	6
Accrued and other current liabilities | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Derivative Liability, Gross		33	17
Counterparty and Cash Collateral Netting, Liabilities	[1]	(22)	(10)
Net Liability included in Consolidated Balance Sheet		$ 11	$ 7
[1]	Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the Company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.

FINANCIAL INSTRUMENTS Effect of

FINANCIAL INSTRUMENTS Effect of Derivative Instrument (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract
Derivative [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net	$ 4	$ (47)

FINANCIAL INSTRUMENTS Notional

FINANCIAL INSTRUMENTS Notional Amounts (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Millions		Mar. 31, 2020	Dec. 31, 2019
Foreign Exchange Contract
Derivative [Line Items]
Derivative, Notional Amount	[1]	$ (344)	$ 26
Commodity Contract [Member]
Derivative [Line Items]
Derivative, Notional Amount		$ 12	$ 11
[1]	Presented net of contracts bought and sold.

FAIR VALUE MEASUREMENTS - Summa

FAIR VALUE MEASUREMENTS - Summary of Recurring Measured Fair Values (Details) - USD ($) $ in Millions		Mar. 31, 2020	Dec. 31, 2019
Liabilities, Fair Value Disclosure [Abstract]
Long Term Debt, Including Debt Due within one year, Fair Value		$ (16,791)	$ (17,251)
Recurring | Level 2
Assets, Fair Value Disclosure [Abstract]
Cash equivalents and restricted cash equivalents	[1]	805	454
Total assets at fair value		839	470
Liabilities, Fair Value Disclosure [Abstract]
Long Term Debt, Including Debt Due within one year, Fair Value	[2]	16,791	17,251
Total liabilities at fair value		16,824	17,268
Recurring | Level 2 | Foreign currency
Assets, Fair Value Disclosure [Abstract]
Foreign Currency Contracts	[3]	34	16
Liabilities, Fair Value Disclosure [Abstract]
Foreign Currency Contracts	[3]	$ 33	$ 17
[1]	Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.
[2]	Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.
[3]	See Note 19 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets.

SEGMENTS AND GEOGRAPHIC REGIO_3

SEGMENTS AND GEOGRAPHIC REGIONS - Summary of Operating Segment Information (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Document Period End Date		Mar. 31, 2020
Net sales		$ 5,221	$ 5,414
Operating EBITDA	[1]	1,321
Equity in earnings of nonconsolidated affiliates		39	40
Pro Forma
Segment Reporting Information [Line Items]
Pro forma Operating EBITDA	[1]		1,430
Equity in earnings of nonconsolidated affiliates	[2]		41
Electronics & Imaging
Segment Reporting Information [Line Items]
Net sales		884	825
Operating EBITDA	[1]	253
Equity in earnings of nonconsolidated affiliates		9	3	[2]
Electronics & Imaging | Pro Forma
Segment Reporting Information [Line Items]
Pro forma Operating EBITDA	[1]		288
Nutrition & Biosciences
Segment Reporting Information [Line Items]
Net sales		1,551	1,535
Operating EBITDA	[1]	385
Equity in earnings of nonconsolidated affiliates		0	0	[2]
Nutrition & Biosciences | Pro Forma
Segment Reporting Information [Line Items]
Pro forma Operating EBITDA	[1]		349
Transportation & Industrial
Segment Reporting Information [Line Items]
Net sales		1,144	1,317
Operating EBITDA	[1]	308
Equity in earnings of nonconsolidated affiliates		1	0	[2]
Transportation & Industrial | Pro Forma
Segment Reporting Information [Line Items]
Pro forma Operating EBITDA	[1]		373
Safety & Construction
Segment Reporting Information [Line Items]
Net sales		1,276	1,283
Operating EBITDA	[1]	368
Equity in earnings of nonconsolidated affiliates		7	8	[2]
Safety & Construction | Pro Forma
Segment Reporting Information [Line Items]
Pro forma Operating EBITDA	[1]		374
Non-core
Segment Reporting Information [Line Items]
Net sales		366	454
Operating EBITDA	[1]	42
Equity in earnings of nonconsolidated affiliates		22
Non-core | Pro Forma
Segment Reporting Information [Line Items]
Pro forma Operating EBITDA	[1]		98
Equity in earnings of nonconsolidated affiliates	[2]		30
Corporate
Segment Reporting Information [Line Items]
Net sales		0	0
Operating EBITDA	[1]	(35)
Equity in earnings of nonconsolidated affiliates		$ 0	0	[2]
Corporate | Pro Forma
Segment Reporting Information [Line Items]
Pro forma Operating EBITDA	[1]		(52)
Income (Loss) From Equity Method Investments [Domain] | Non-core
Segment Reporting Information [Line Items]
Restructuring Charges			$ 1
[1]	A reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA and pro forma Operating EBITDA, as applicable, is provided below.
[2]	Represents equity in earnings (losses) of nonconsolidated affiliates included in pro forma Operating EBITDA, the Company's measure of profit/loss for segment reporting purposes, which excludes significant items. Accordingly, the Non-Core segment presented above excludes a restructuring charge of $1 million which is presented in "Equity in earnings of nonconsolidated affiliates" in the Company's interim Consolidated Statement of Operations.

SEGMENTS AND GEOGRAPHIC REGIO_4

SEGMENTS AND GEOGRAPHIC REGIONS - Summary of Reconciliation of Operating EBITDA (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2020		Mar. 31, 2019
Segment Reporting Information [Line Items]
Loss from continuing operations, net of tax		$ (610)		$ (74)
Provision for (benefit from) income taxes on continuing operations		44		(91)
Loss from continuing operations before income taxes		(566)		(165)
Depreciation and amortization		772
Interest income		2	[1]	40
Interest expense		183		151
Non-operating pension/OPEB benefit		11	[1]	21
Foreign exchange gains (losses), net		(8)	[1]	(61)
Significant items	[2]	(947)
Operating EBITDA	[3]	1,321
Adjusted for Significant Item [Member]
Segment Reporting Information [Line Items]
Interest expense		$ 173
Pro Forma
Segment Reporting Information [Line Items]
Loss from continuing operations, net of tax				(74)
Provision for (benefit from) income taxes on continuing operations				(91)
Loss from continuing operations before income taxes				(165)
Pro Forma Adjustments	[4]			122
Depreciation and amortization				527
Interest income	[1]			40
Interest expense				180
Non-operating pension/OPEB benefit	[1]			21
Foreign exchange gains (losses), net	[1]			(61)
Costs Historically Allocated to the Materials Science and Agriculture Businesses	[5]			256
Significant items	[2]			(510)
Pro forma Operating EBITDA	[3]			$ 1,430
[1]	Included in "Sundry income (expense) - net."
[2]	The significant items for the three months ended March 31, 2020, are presented on an as reported basis. The adjusted significant items for the three months ended March 31, 2019 are presented on a pro forma basis.
[3]	A reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA and pro forma Operating EBITDA, as applicable, is provided below.
[4]	For the three months ended March 31, 2019 , operating EBITDA is on a pro forma basis. The pro forma adjustment reflects the net pro forma impact of items directly attributable to the Transactions, as applicable.
[5]	Costs previously allocated to the materials science and agriculture businesses that did not meet the definition of expenses related to discontinued operations in accordance with ASC 205.

SEGMENTS AND GEOGRAPHIC REGIO_5

SEGMENTS AND GEOGRAPHIC REGIONS - Summary of Certain Items by Segment (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2020		Mar. 31, 2019
Integration And Separation Costs	[1]	$ (197)
Restructuring and asset related charges - net	[2]	(134)
Goodwill impairment charge		(533)	[3]	$ 0
Asset Impairment Charges	[4]	(270)
Gain (Loss) on Disposition of Business	[5]	197
Significant items	[6]	(947)
Electronics & Imaging
Restructuring and asset related charges - net	[2]	(4)
Goodwill impairment charge		0
Gain (Loss) on Disposition of Business	[5]	197
Significant items		193
Nutrition & Biosciences
Restructuring and asset related charges - net	[2]	(6)
Goodwill impairment charge		0
Significant items		(6)
Transportation & Industrial
Restructuring and asset related charges - net	[2]	(25)
Goodwill impairment charge		0
Significant items		(25)
Safety & Construction
Restructuring and asset related charges - net	[2]	(25)
Goodwill impairment charge		0
Significant items		(25)
Non-core
Restructuring and asset related charges - net	[2]	0
Goodwill impairment charge	[3]	(533)
Asset Impairment Charges	[4]	(270)
Significant items		(803)
Corporate
Integration And Separation Costs	[1]	(197)
Restructuring and asset related charges - net	[2]	(74)
Significant items		(281)
Pro Forma
Integration And Separation Costs	[7]			(438)
Restructuring and asset related charges - net	[8]			(72)
Significant items	[6]			(510)
Pro Forma | Electronics & Imaging
Restructuring and asset related charges - net	[8]			0
Significant items				0
Pro Forma | Nutrition & Biosciences
Restructuring and asset related charges - net	[8]			(27)
Significant items				(27)
Pro Forma | Transportation & Industrial
Restructuring and asset related charges - net	[8]			0
Significant items				0
Pro Forma | Safety & Construction
Restructuring and asset related charges - net	[8]			(2)
Significant items				(2)
Pro Forma | Non-core
Restructuring and asset related charges - net	[8]			1
Significant items				1
Pro Forma | Corporate
Integration And Separation Costs	[7]			(438)
Restructuring and asset related charges - net	[8]			(44)
Significant items				$ (482)
N&B financing [Member]
Financing Fee Amortization	[9]	10
N&B financing [Member] | Corporate
Financing Fee Amortization	[9]	$ 10
[1]	Integration and separation costs related to the post-Merger integration and the intended separation of the N&B Business.
[2]	Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.
[3]	See Note 11 for additional information.
[4]	See Note 5 for additional information.
[5]	Reflected in "Sundry income (expense) - net." Refer to Note 3 for additional information.
[6]	The significant items for the three months ended March 31, 2020, are presented on an as reported basis. The adjusted significant items for the three months ended March 31, 2019 are presented on a pro forma basis.
[7]	Integration and separation costs related to the Merger, post-Merger integration and business separation activities.
[8]	Includes Board approved restructuring plans and asset related charges. See Note 5 for additional information.
[9]	Reflected in "Interest expense" and relates to the intended separation of the N&B Business.